{"id":"dexmedetomidine-hydrochloride","rwe":[],"_fda":{"id":"1896a96e-25f8-494e-9a96-6463b52fb102","set_id":"1896a96e-25f8-494e-9a96-6463b52fb102","openfda":{"unii":["1018WH7F9I"],"route":["INTRAVENOUS"],"rxcui":["309710"],"spl_id":["1896a96e-25f8-494e-9a96-6463b52fb102"],"brand_name":["Dexmedetomidine Hydrochloride"],"spl_set_id":["1896a96e-25f8-494e-9a96-6463b52fb102"],"package_ndc":["65219-642-01","65219-642-02"],"product_ndc":["65219-642"],"generic_name":["DEXMEDETOMIDINE HYDROCHLORIDE"],"product_type":["HUMAN PRESCRIPTION DRUG"],"substance_name":["DEXMEDETOMIDINE HYDROCHLORIDE"],"manufacturer_name":["Fresenius Kabi USA, LLC"],"application_number":["ANDA201072"],"is_original_packager":[true]},"version":"1","pregnancy":["8.1 Pregnancy Risk Summary Available data from published randomized controlled trials and case reports over several decades of use with intravenously administered dexmedetomidine during pregnancy have not identified a drug-associated risk of major birth defects and miscarriage; however, the reported exposures occurred after the first trimester. Most of the available data are based on studies with exposures that occurred at the time of caesarean section delivery, and these studies have not identified an adverse effect on maternal outcomes or infant Apgar scores. Available data indicate that dexmedetomidine crosses the placenta. In animal reproduction studies, fetal toxicity that lower fetal viability and reduced live fetuses occurred with subcutaneous administration of dexmedetomidine to pregnant rats during organogenesis at doses 1.8 times the maximum recommended human dose (MRHD) of 17.8 mcg/kg/day. Developmental toxicity (low pup weights and adult offspring weights, decreased F1 grip strength, increased early implantation loss and decreased viability of second-generation offspring) occurred when pregnant rats were subcutaneously administered dexmedetomidine at doses less than the clinical dose from late pregnancy through lactation and weaning (see Data ) . The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively. Data Animal Data Increased post-implantation losses and reduced live fetuses in the presence of maternal toxicity (i.e. decreased body weight) were noted in a rat embryo-fetal development study in which pregnant dams were administered subcutaneous doses of dexmedetomidine 200 mcg/kg/day (equivalent to 1.8 times the intravenous MRHD of 17.8 mcg/kg/day based on body surface area [BSA]) during the period of organogenesis (Gestation Day [GD] 6 to 15). No malformations were reported. No malformations or embryo-fetal toxicity were noted in a rabbit embryo-fetal development study in which pregnant does were administered dexmedetomidine intravenously at doses of up to 96 mcg/kg/day (approximately half the human exposure at the MRHD based on AUC) during the period of organogenesis (GD 6 to 18). Reduced pup and adult offspring birth weights, and grip strength were reported in a rat developmental toxicology study in which pregnant females were administered dexmedetomidine subcutaneously at doses of 8 mcg/kg/day (0.07 times the MRHD based on BSA) during late pregnancy through lactation and weaning (GD 16 to postnatal day [PND] 25). Decreased viability of second generation offspring and an increase in early implantation loss along with delayed motor development occurred in the 32 mcg/kg/day group (equivalent to less than the clinical dose based on BSA) when first generation offspring were allowed to mate. This study limited dosing to hard palate closure (GD 15 to 18) through weaning instead of dosing from implantation (GD 6 to 7) to weaning (PND 21). In a study in the pregnant rat, placental transfer of dexmedetomidine was observed when radiolabeled dexmedetomidine was administered subcutaneously."],"dependence":["9.3 Dependence The dependence potential of Dexmedetomidine Injection has not been studied in humans. However, since studies in rodents and primates have demonstrated that Dexmedetomidine Injection exhibits pharmacologic actions similar to those of clonidine, it is possible that Dexmedetomidine Injection may produce a clonidine-like withdrawal syndrome upon abrupt discontinuation [see Warnings and Precautions ( 5.5 )] ."],"overdosage":["10 OVERDOSAGE The tolerability of Dexmedetomidine Injection was studied in one study in which healthy adult subjects were administered doses at and above the recommended dose of 0.2 to 0.7 mcg/kg/hr. The maximum blood concentration achieved in this study was approximately 13 times the upper boundary of the therapeutic range. The most notable effects observed in two subjects who achieved the highest doses were first degree atrioventricular block and second-degree heart block. No hemodynamic compromise was noted with the atrioventricular block and the heart block resolved spontaneously within one minute. Five adult patients received an overdose of Dexmedetomidine Hydrochloride in the intensive care unit sedation studies. Two of these patients had no symptoms reported; one patient received a 2 mcg/kg loading dose over 10 minutes (twice the recommended loading dose) and one patient received a maintenance infusion of 0.8 mcg/kg/hr. Two other patients who received a 2 mcg/kg loading dose over 10 minutes, experienced bradycardia and/or hypotension. One patient who received a loading bolus dose of undiluted Dexmedetomidine Injection (19.4 mcg/kg), had cardiac arrest from which he was successfully resuscitated."],"description":["11 DESCRIPTION Dexmedetomidine Injection, USP is a sterile, nonpyrogenic solution suitable for intravenous infusion following dilution. Dexmedetomidine Injection contains dexmedetomidine hydrochloride as the active pharmaceutical ingredient. Dexmedetomidine hydrochloride is a central alpha 2 -adrenergic agonist. Dexmedetomidine hydrochloride is the S-enantiomer of medetomidine and is chemically described as (+)-4-(S)-[1-(2,3-dimethylphenyl)ethyl]-1H-imidazole monohydrochloride, and the structural formula is: Dexmedetomidine hydrochloride is a white or almost white powder that is freely soluble in water and has a pKa of 7.1. Its partition coefficient in-octanol: water at pH 7.4 is 2.89. Dexmedetomidine Injection, USP is supplied as a clear, colorless, isotonic solution with a pH of 4.5 to 7.0. Each mL contains 118 mcg of dexmedetomidine hydrochloride equivalent to 100 mcg (0.1 mg) of dexmedetomidine, 9 mg of sodium chloride, 597 mcg of sodium acetate trihydrate and 27 mcg of glacial acetic acid in water. The solution is preservative-free. dexme-struc-01.jpg"],"how_supplied":["16 HOW SUPPLIED/STORAGE AND HANDLING Dexmedetomidine Injection, USP, is a clear, colorless solution available as: Product Code Unit of Sale Strength Each RF462102 NDC 65219-642-02 Unit of 25 200 mcg (dexmedetomidine) per 2 mL (100 mcg (dexmedetomidine) per mL) NDC 65219-642-01 2 mL single-dose glass vial This product is RFID-enabled. 462102 NDC 63323-421-02 Unit of 25 200 mcg (dexmedetomidine) per 2 mL (100 mcg (dexmedetomidine) per mL) NDC 63323-421-01 2 mL single-dose glass vial Store at 20°C to 25°C (68°F to 77°F); excursions permitted between 15°C to 30°C (59°F to 86°F). [See USP Controlled Room Temperature.] The container closure is not made with natural rubber latex. Discard unused portion. Do not use if product is discolored or if precipitate matter is present."],"geriatric_use":["8.5 Geriatric Use Intensive Care Unit Sedation A total of 729 patients in the clinical studies were 65 years of age and over. A total of 200 patients were 75 years of age and over. In patients greater than 65 years of age, a higher incidence of bradycardia and hypotension was observed following administration of Dexmedetomidine Hydrochloride [see Warnings and Precautions ( 5.2 )] . Therefore, a dose reduction may be considered in patients over 65 years of age [see Dosage and Administration ( 2.2 , 2.3 ), Clinical Pharmacology ( 12.3 )] . Procedural Sedation A total of 131 patients in the clinical studies were 65 years of age and over. A total of 47 patients were 75 years of age and over. Hypotension occurred in a higher incidence in Dexmedetomidine Injection-treated patients 65 years or older (72%) and 75 years or older (74%) as compared to patients <65 years (47%). A reduced loading dose of 0.5 mcg/kg given over 10 minutes is recommended and a reduction in the maintenance infusion should be considered for patients greater than 65 years of age."],"pediatric_use":["8.4 Pediatric Use Sedation for Non-Invasive Procedures The safety and effectiveness of Dexmedetomidine Injection have not been established in pediatric patients less than 1 month of age. Pediatric use information is approved for Hospira Inc.'s PRECEDEX TM (dexmedetomidine hydrochloride) injection. However, due to Hospira Inc.'s marketing exclusivity rights, this drug product is not labeled with that information. ICU Sedation The safety and efficacy of Dexmedetomidine Injection have not been established in pediatric patients for ICU sedation. One assessor-blinded trial in pediatric patients and two open label studies in neonates were conducted to assess efficacy for ICU sedation. These studies did not meet their primary efficacy endpoints and the safety data submitted were insufficient to fully characterize the safety profile of Dexmedetomidine Injection for these patient populations."],"effective_time":"20260123","clinical_studies":["14 CLINICAL STUDIES The safety and efficacy of Dexmedetomidine Injection has been evaluated in four randomized, double-blind, placebo-controlled multicenter clinical trials in 1,185 adult patients. 14.1 Intensive Care Unit Sedation Two randomized, double-blind, parallel-group, placebo-controlled multicenter clinical trials included 754 adult patients being treated in a surgical intensive care unit. All patients were initially intubated and received mechanical ventilation. These trials evaluated the sedative properties of Dexmedetomidine Hydrochloride by comparing the amount of rescue medication (midazolam in one trial and propofol in the second) required to achieve a specified level of sedation (using the standardized Ramsay Sedation Scale) between Dexmedetomidine Hydrochloride and placebo from onset of treatment to extubation or to a total treatment duration of 24 hours. The Ramsay Level of Sedation Scale is displayed in Table 12 . Table 12: Ramsay Level of Sedation Scale Clinical Score Level of Sedation Achieved 6 Asleep, no response 5 Asleep, sluggish response to light glabellar tap or loud auditory stimulus 4 Asleep, but with brisk response to light glabellar tap or loud auditory stimulus 3 Patient responds to commands 2 Patient cooperative, oriented, and tranquil 1 Patient anxious, agitated, or restless In the first study, 175 adult patients were randomized to receive placebo and 178 to receive dexmedetomidine hydrochloride by intravenous infusion at a dose of 0.4 mcg/kg/hr (with allowed adjustment between 0.2 and 0.7 mcg/kg/hr) following an initial loading infusion of one mcg/kg intravenous over 10 minutes. The study drug infusion rate was adjusted to maintain a Ramsay sedation score of ≥3. Patients were allowed to receive “rescue” midazolam as needed to augment the study drug infusion. In addition, morphine sulfate was administered for pain as needed. The primary outcome measure for this study was the total amount of rescue medication (midazolam) needed to maintain sedation as specified while intubated. Patients randomized to placebo received significantly more midazolam than patients randomized to dexmedetomidine hydrochloride (see Table 13 ). A second prospective primary analysis assessed the sedative effects of dexmedetomidine hydrochloride by comparing the percentage of adult patients who achieved a Ramsay sedation score of ≥3 during intubation without the use of additional rescue medication. A significantly greater percentage of adult patients in the dexmedetomidine hydrochloride group maintained a Ramsay sedation score of ≥3 without receiving any midazolam rescue compared to the placebo group (see Table 13 ). Table 13: Midazolam Use as Rescue Medication During Intubation (ITT) Study One ITT (intent-to-treat) population includes all randomized patients. * ANOVA model with treatment center. ** Chi-square. Placebo (N=175) Dexmedetomidine hydrochloride (N=178) p-value Mean Total Dose (mg) of Midazolam Standard deviation 19 mg 53 mg 5 mg 19 mg 0.0011* Categorized Midazolam Use 0 mg 43 (25%) 108 (61%) ˂0.001** 0-4 mg 34 (19%) 36 (20%) ˃4 mg 98 (56%) 34 (19%) A prospective secondary analysis assessed the dose of morphine sulfate administered to adult patients in the Dexmedetomidine Hydrochloride and placebo groups. On average, Dexmedetomidine Hydrochloride-treated patients received less morphine sulfate for pain than placebo-treated patients (0.47 versus 0.83 mg/h). In addition, 44% (79 of 178 patients) of Dexmedetomidine Hydrochloride patients received no morphine sulfate for pain versus 19% (33 of 175 patients) in the placebo group. In a second study, 198 adult patients were randomized to receive placebo and 203 to receive Dexmedetomidine Hydrochloride by intravenous infusion at a dose of 0.4 mcg/kg/hr (with allowed adjustment between 0.2 and 0.7 mcg/kg/hr) following an initial loading infusion of one mcg/kg intravenous over 10 minutes. The study drug infusion was adjusted to maintain a Ramsay sedation score of ≥3. Patients were allowed to receive “rescue” propofol as needed to augment the study drug infusion. In addition, morphine sulfate was administered as needed for pain. The primary outcome measure for this study was the total amount of rescue medication (propofol) needed to maintain sedation as specified while intubated. Adult patients randomized to placebo received significantly more propofol than adult patients randomized to Dexmedetomidine Hydrochloride (see Table 14 ). A significantly greater percentage of adult patients in the dexmedetomidine hydrochloride group compared to the placebo group maintained a Ramsay sedation score of ≥3 without receiving any propofol rescue (see Table 14 ). Table 14: Propofol Use as Rescue Medication During Intubation (ITT) Study Two * ANOVA model with treatment center. ** Chi-square. Placebo (N = 198) Dexmedetomidine Hydrochloride (N =203) p-value Mean Total Dose (mg) of Propofol Standard deviation 513 mg 782 mg 72 mg 249 mg <0.0001* Categorized Propofol Use 0 mg 47 (24%) 122 (60%) <0.001** 0–50 mg 30 (15%) 43 (21%) >50 mg 121 (61%) 38 (19%) A prospective secondary analysis assessed the dose of morphine sulfate administered to adult patients in the dexmedetomidine hydrochloride and placebo groups. On average, dexmedetomidine hydrochloride-treated patients received less morphine sulfate for pain than placebo-treated patients (0.43 versus 0.89 mg/h). In addition, 41% (83 of 203 patients) of Dexmedetomidine Hydrochloride patients received no morphine sulfate for pain versus 15% (30 of 198 patients) in the placebo group. In a controlled clinical trial, dexmedetomidine hydrochloride was compared to midazolam for ICU sedation exceeding 24 hours duration. Dexmedetomidine Hydrochloride was not shown to be superior to midazolam for the primary efficacy endpoint, the percent of time patients were adequately sedated (81% versus 81%). In addition, administration of dexmedetomidine hydrochloride for longer than 24 hours was associated with tolerance, tachyphylaxis, and a dose-related increase in adverse events [see Adverse Reactions ( 6.1 )] . 14.2 Procedural Sedation Adult Patients The safety and efficacy of Dexmedetomidine Injection for sedation of non-intubated adult patients prior to and/or during surgical and other procedures was evaluated in two randomized, double-blind, placebo-controlled multicenter clinical trials. Study 1 evaluated the sedative properties of Dexmedetomidine Injection in adult patients having a variety of elective surgeries/procedures performed under monitored anesthesia care. Study 2 evaluated Dexmedetomidine Injection in adult patients undergoing awake fiberoptic intubation prior to a surgical or diagnostic procedure. In Study 1, the sedative properties of Dexmedetomidine Injection were evaluated by comparing the percent of adult patients not requiring rescue midazolam to achieve a specified level of sedation using the standardized Observer's Assessment of Alertness/Sedation Scale (see Table 15 ). Table 15: Observer's Assessment of Alertness/Sedation Assessment Categories Responsiveness Speech Facial Expression Eyes Composite Score Responds readily to name spoken in normal tone Normal Normal Clear, no ptosis 5 (alert) Lethargic response to name spoken in normal tone Mild slowing or thickening Mild relaxation Glazed or mild ptosis (less than half the eye) 4 Responds only after name is called loudly and/or repeatedly Slurring or prominent slowing Marked relaxation (slack jaw) Glazed and marked ptosis (half the eye or more) 3 Responds only after mild prodding or shaking Few recognizable words - - 2 Does not respond to mild prodding or shaking - - - 1 (deep sleep) Adult patients were randomized to receive a loading infusion of either Dexmedetomidine Injection 1 mcg/kg, Dexmedetomidine Injection 0.5 mcg/kg, or placebo (normal saline) given over 10 minutes and followed by a maintenance infusion started at 0.6 mcg/kg/hr. The maintenance infusion of study drug could be titrated from 0.2 mcg/kg/hr to 1 mcg/kg/hr to achieve the targeted sedation score (Observer's Assessment of Alertness/Sedation Scale ≤4). Adult patients were allowed to receive rescue midazolam as needed to achieve and/or maintain an Observer's Assessment of Alertness/Sedation Scale ≤4. After achieving the desired level of sedation, a local or regional anesthetic block was performed. Demographic characteristics were similar between the Dexmedetomidine Injection and comparator groups. Efficacy results showed that Dexmedetomidine Injection was more effective than the comparator group when used to sedate non-intubated patients requiring monitored anesthesia care during surgical and other procedures (see Table 15 ). In Study 2, the sedative properties of Dexmedetomidine Injection were evaluated by comparing the percent of adult patients requiring rescue midazolam to achieve or maintain a specified level of sedation using the Ramsay Sedation Scale score ≥2 (see Table 12 ). Adult patients were randomized to receive a loading infusion of Dexmedetomidine Injection 1 mcg/kg or placebo (normal saline) given over 10 minutes and followed by a fixed maintenance infusion of 0.7 mcg/kg/hr. After achieving the desired level of sedation, topicalization of the airway occurred. Adult patients were allowed to receive rescue midazolam as needed to achieve and/or maintain a Ramsay Sedation Scale ≥2. Demographic characteristics were similar between the Dexmedetomidine Injection and comparator groups. For efficacy results see Table 16 . Table 16: Key Efficacy Results of Adult Procedural Sedation Studies a Based on ITT population defined as all randomized and treated patients. b Normal approximation to the binomial with continuity correction. Study Loading Infusion Treatment Arm Number of Patients Enrolled a % Not Requiring Midazolam Rescue Confidence b Interval on the Difference vs. Placebo Mean (SD) Total Dose (mg) of Rescue Midazolam Required Confidence b Intervals of the Mean Rescue Dose Dexmedetomidine 0.5 mcg/kg 134 40 37 (27, 48) 1.4 (1.7) -2.7 (-3.4, -2.0) Study 1 Dexmedetomidine 1 mcg/kg 129 54 51 (40, 62) 0.9 (1.5) -3.1 (-3.8, -2.5) Placebo 63 3 – 4.1 (3.0) – Study 2 Dexmedetomidine 1 mcg/kg 55 53 39 (20, 57) 1.1 (1.5) -1.8 (-2.7, -0.9) Placebo 50 14 – 2.9 (3.0) – Pediatric use information is approved for Hospira Inc.'s PRECEDEX TM (dexmedetomidine hydrochloride) injection. However, due to Hospira Inc.'s marketing exclusivity rights, this drug product is not labeled with that information."],"pharmacodynamics":["12.2 Pharmacodynamics In a study in healthy adult volunteers (N = 10), respiratory rate and oxygen saturation remained within normal limits and there was no evidence of respiratory depression when Dexmedetomidine Injection was administered by intravenous infusion at doses within the recommended dose range (0.2-0.7 mcg/kg/hr)."],"pharmacokinetics":["12.3 Pharmacokinetics Following intravenous administration to adults, dexmedetomidine exhibits the following pharmacokinetic parameters: a rapid distribution phase with a distribution half-life (t 1/2 ) of approximately 6 minutes; a terminal elimination half-life (t 1/2 ) of approximately 2 hours; and steady-state volume of distribution (V ss ) of approximately 118 liters. Clearance is estimated to be approximately 39 L/h. The mean body weight associated with this clearance estimate was 72 kg. Dexmedetomidine exhibits linear pharmacokinetics in the dosage range of 0.2 to 0.7 mcg/kg/hr when administered to adults by intravenous infusion for up to 24 hours. Table 10 shows the main pharmacokinetic parameters when Dexmedetomidine Injection was infused (after appropriate loading doses) at maintenance infusion rates of 0.17 mcg/kg/hr (target plasma concentration of 0.3 ng/mL) for 12 and 24 hours, 0.33 mcg/kg/hr (target plasma concentration of 0.6 ng/mL) for 24 hours, and 0.70 mcg/kg/hr (target plasma concentration of 1.25 ng/mL) for 24 hours. Table 10: Mean ± SD Pharmacokinetic Parameters in Adults Abbreviations: t 1/2 = half-life, CL = clearance, V ss = steady-state volume of distribution. * Presented as harmonic mean and pseudo standard deviation. # Mean C ss = Average steady-state concentration of Dexmedetomidine Injection. The mean C ss was calculated based on post-dose sampling from 2.5 to 9 hours samples for 12 hour infusion and post-dose sampling from 2.5 to 18 hours for 24 hour infusions. Parameter Loading Infusion (min)/Total Infusion Duration (hrs) 10 min/12 hrs 10 min/24 hrs 10 min/24 hrs 35 min/24 hrs Dexmedetomidine Target Plasma Concentration (ng/mL) and Dose (mcg/kg/hr) 0.3/0.17 0.3/0.17 0.6/0.33 1.25/0.70 t 1/2 *, hour 1.78 ± 0.30 2.22 ± 0.59 2.23 ± 0.21 2.50 ± 0.61 CL, liter/hour 46.3 ± 8.3 43.1 ± 6.5 35.3 ± 6.8 36.5 ± 7.5 V ss , liter 88.7 ± 22.9 102.4 ± 20.3 93.6 ± 17.0 99.6 ± 17.8 Avg C ss # , ng/mL 0.27 ± 0.05 0.27 ± 0.05 0.67 ± 0.10 1.37 ± 0.20 The loading doses for each of the above indicated groups were 0.5, 0.5, 1 and 2.2 mcg/kg, respectively. Dexmedetomidine pharmacokinetic parameters in adults after Dexmedetomidine Injection maintenance doses of 0.2 to 1.4 mcg/kg/hr for >24 hours were similar to the pharmacokinetic (PK) parameters after Dexmedetomidine Injection maintenance dosing for <24 hours in other studies. The values for clearance (CL), volume of distribution (V), and t 1/2 were 39.4 L/hr, 152 L, and 2.67 hours, respectively. Distribution The steady-state volume of distribution (V ss ) of dexmedetomidine was approximately 118 liters. Dexmedetomidine protein binding was assessed in the plasma of normal healthy male and female subjects. The average protein binding was 94% and was constant across the different plasma concentrations tested. Protein binding was similar in males and females. The fraction of Dexmedetomidine Injection that was bound to plasma proteins was significantly decreased in subjects with hepatic impairment compared to healthy subjects. The potential for protein binding displacement of dexmedetomidine by fentanyl, ketorolac, theophylline, digoxin and lidocaine was explored in vitro , and negligible changes in the plasma protein binding of Dexmedetomidine Injection were observed. The potential for protein binding displacement of phenytoin, warfarin, ibuprofen, propranolol, theophylline and digoxin by Dexmedetomidine Injection was explored in vitro and none of these compounds appeared to be significantly displaced by Dexmedetomidine Injection. Elimination Metabolism Dexmedetomidine undergoes almost complete biotransformation with very little unchanged dexmedetomidine excreted in urine and feces. Biotransformation involves both direct glucuronidation as well as cytochrome P450 mediated metabolism. The major metabolic pathways of dexmedetomidine are: direct N-glucuronidation to inactive metabolites; aliphatic hydroxylation (mediated primarily by CYP2A6 with a minor role of CYP1A2, CYP2E1, CYP2D6 and CYP2C19) of dexmedetomidine to generate 3-hydroxy-dexmedetomidine, the glucuronide of 3-hydroxy-dexmedetomidine, and 3-carboxy-dexmedetomidine; and N-methylation of dexmedetomidine to generate 3-hydroxy N-methyl-dexmedetomidine, 3-carboxy N-methyl-dexmedetomidine, and dexmedetomidine-N-methyl O- glucuronide. Excretion The terminal elimination half-life (t 1/2 ) of dexmedetomidine is approximately 2 hours and clearance is estimated to be approximately 39 L/h. A mass balance study demonstrated that after nine days an average of 95% of the radioactivity, following intravenous administration of radiolabeled dexmedetomidine, was recovered in the urine and 4% in the feces. No unchanged dexmedetomidine was detected in the urine. Approximately 85% of the radioactivity recovered in the urine was excreted within 24 hours after the infusion. Fractionation of the radioactivity excreted in urine demonstrated that products of N-glucuronidation accounted for approximately 34% of the cumulative urinary excretion. In addition, aliphatic hydroxylation of parent drug to form 3-hydroxy-dexmedetomidine, the glucuronide of 3-hydroxy-dexmedetomidine, and 3-carboxylic acid-dexmedetomidine together represented approximately 14% of the dose in urine. N-methylation of dexmedetomidine to form 3-hydroxy N-methyl dexmedetomidine, 3-carboxy N-methyl dexmedetomidine, and N-methyl O-glucuronide dexmedetomidine accounted for approximately 18% of the dose in urine. The N-Methyl metabolite itself was a minor circulating component and was undetected in urine. Approximately 28% of the urinary metabolites have not been identified. Specific Populations Male and Female Patients There was no observed difference in Dexmedetomidine Injection pharmacokinetics due to sex. Geriatric Patients The pharmacokinetic profile of Dexmedetomidine Injection was not altered by age. There were no differences in the pharmacokinetics of Dexmedetomidine Injection in young (18-40 years), middle age (41-65 years), and elderly (>65 years) subjects. Pediatric Patients Pediatric use information is approved for Hospira Inc.'s PRECEDEX TM (dexmedetomidine hydrochloride) injection. However, due to Hospira Inc.'s marketing exclusivity rights, this drug product is not labeled with that information. Patients with Hepatic Impairment In adult subjects with varying degrees of hepatic impairment (Child-Pugh Class A, B, or C), clearance values for Dexmedetomidine Injection were lower than in healthy subjects. The mean clearance values for patients with mild, moderate, and severe hepatic impairment were 74%, 64% and 53% of those observed in the normal healthy adult subjects, respectively. Mean clearances for free drug were 59%, 51% and 32% of those observed in the normal healthy adult subjects, respectively. Although Dexmedetomidine Injection is dosed to effect, it may be necessary to consider dose reduction in subjects with hepatic impairment [see Dosage and Administration ( 2.2 ), Warnings and Precautions ( 5.8 )] . Patients with Renal Impairment Dexmedetomidine Injection pharmacokinetics (C max , T max , AUC, t 1/2 , CL, and V ss ) were not significantly different in patients with severe renal impairment (creatinine clearance: <30 mL/min) compared to healthy subjects. Drug Interaction Studies In vitro studies: In vitro studies in human liver microsomes demonstrated no evidence of cytochrome P450 mediated drug interactions that are likely to be of clinical relevance."],"adverse_reactions":["6 ADVERSE REACTIONS The following clinically significant adverse reactions are described elsewhere in the labeling: • Hypotension, bradycardia and sinus arrest [see Warnings and Precautions ( 5.2 )] • Transient hypertension [see Warnings and Precautions ( 5.3 )] • The most common adverse reactions (incidence >2%) in adults are hypotension, bradycardia, and dry mouth. ( 6.1 ) • Adverse reactions in adults, associated with infusions ˃24 hours in duration include ARDS, respiratory failure, and agitation. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Fresenius Kabi USA, LLC at 1-800-551-7176 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reactions rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. Most common treatment-emergent adverse reactions, occurring in greater than 2% of adult patients in both Intensive Care Unit and procedural sedation studies include hypotension, bradycardia and dry mouth. Intensive Care Unit Sedation Adverse reaction information is derived from the continuous infusion trials of Dexmedetomidine Injection for sedation in the Intensive Care Unit setting in which 1,007 adult patients received Dexmedetomidine Hydrochloride. The mean total dose was 7.4 mcg/kg (range: 0.8 to 84.1), mean dose per hour was 0.5 mcg/kg/hr (range: 0.1 to 6.0) and the mean duration of infusion of 15.9 hours (range: 0.2 to 157.2). The population was between 17 to 88 years of age, 43% ≥65 years of age, 77% male and 93% Caucasian. Treatment-emergent adverse reactions occurring at an incidence of >2% are provided in Table 3 . The most frequent adverse reactions were hypotension, bradycardia and dry mouth [see Warnings and Precautions ( 5.2 )] . Table 3: Adverse Reactions with an Incidence ˃2%-Adult Intensive Care Unit Sedation Population ˂24 hours* * 26 subjects in the all Dexmedetomidine Hydrochloride group and 10 subjects in the randomized Dexmedetomidine Hydrochloride group had exposure for greater than 24 hours. Adverse Event All Dexmedetomidine Hydrochloride (N = 1007) (%) Randomized Dexmedetomidine Hydrochloride (N = 798) (%) Placebo (N = 400) (%) Propofol (N = 188) (%) Hypotension 25% 24% 12% 13% Hypertension 12% 13% 19% 4% Nausea 9% 9% 9% 11% Bradycardia 5% 5% 3% 0 Atrial Fibrillation 4% 5% 3% 7% Pyrexia 4% 4% 4% 4% Dry Mouth 4% 3% 1% 1% Vomiting 3% 3% 5% 3% Hypovolemia 3% 3% 2% 5% Atelectasis 3% 3% 3% 6% Pleural Effusion 2% 2% 1% 6% Agitation 2% 2% 3% 1% Tachycardia 2% 2% 4% 1% Anemia 2% 2% 2% 2% Hyperthermia 2% 2% 3% 0 Chills 2% 2% 3% 2% Hyperglycemia 2% 2% 2% 3% Hypoxia 2% 2% 2% 3% Post-procedural Hemorrhage 2% 2% 3% 4% Pulmonary Edema 1% 1% 1% 3% Hypocalcemia 1% 1% 0 2% Acidosis 1% 1% 1% 2% Urine Output Decreased 1% 1% 0 2% Sinus Tachycardia 1% 1% 1% 2% Ventricular Tachycardia <1% 1% 1% 5% Wheezing <1% 1% 0 2% Edema Peripheral <1% 0 1% 2% Adverse reaction information was also derived from the placebo-controlled, continuous infusion trials of Dexmedetomidine Hydrochloride for sedation in the surgical intensive care unit setting in which 387 adult patients received Dexmedetomidine Hydrochloride for less than 24 hours. The most frequently observed treatment-emergent adverse events included hypotension, hypertension, nausea, bradycardia, fever, vomiting, hypoxia, tachycardia and anemia (see Table 4 ). Table 4: Treatment-Emergent Adverse Events Occurring in >1% of All Dexmedetomidine-Treated Adult Patients in the Randomized Placebo- Controlled Continuous Infusion <24 Hours ICU Sedation Studies Adverse Event Randomized Dexmedetomidine (N = 387) Placebo (N = 379) Hypotension 28% 13% Hypertension 16% 18% Nausea 11% 9% Bradycardia 7% 3% Fever 5% 4% Vomiting 4% 6% Atrial Fibrillation 4% 3% Hypoxia 4% 4% Tachycardia 3% 5% Hemorrhage 3% 4% Anemia 3% 2% Dry Mouth 3% 1% Rigors 2% 3% Agitation 2% 3% Hyperpyrexia 2% 3% Pain 2% 2% Hyperglycemia 2% 2% Acidosis 2% 2% Pleural Effusion 2% 1% Oliguria 2% <1% Thirst 2% <1% In a controlled clinical trial, Dexmedetomidine Hydrochloride was compared to midazolam for ICU sedation exceeding 24 hours duration in adult patients. Key treatment emergent adverse events occurring in dexmedetomidine or midazolam treated adult patients in the randomized active comparator continuous infusion long-term intensive care unit sedation study are provided in Table 5 . The number (%) of adult subjects who had a dose-related increase in treatment-emergent adverse events by maintenance adjusted dose rate range in the Dexmedetomidine Hydrochloride group is provided in Table 6 . Table 5: Key Treatment-Emergent Adverse Events Occurring in Dexmedetomidine-or Midazolam-Treated Adult Patients in the Randomized Active Comparator Continuous Infusion Long-Term Intensive Care Unit Sedation Study † Includes any type of hypertension. 1 Hypotension was defined in absolute terms as Systolic blood pressure of <80 mmHg or Diastolic blood pressure of <50 mmHg or in relative terms as ≤30% lower than pre-study drug infusion value. 2 Bradycardia was defined in absolute terms as <40 bpm or in relative terms as ≤30% lower than pre-study drug infusion value. 3 Hypertension was defined in absolute terms as Systolic blood pressure >180 mmHg or Diastolic blood pressure of >100 mmHg or in relative terms as ≥30% higher than pre-study drug infusion value. 4 Tachycardia was defined in absolute terms as >120 bpm or in relative terms as ≥30% greater than pre-study drug infusion value. Adverse Event Dexmedetomidine (N = 244) Midazolam (N = 122) Hypotension 1 56% 56% Hypotension Requiring Intervention 28% 27% Bradycardia 2 42% 19% Bradycardia Requiring Intervention 5% 1% Systolic Hypertension 3 28% 42% Tachycardia 4 25% 44% Tachycardia Requiring Intervention 10% 10% Diastolic Hypertension 3 12% 15% Hypertension 3 11% 15% Hypertension Requiring Intervention † 19% 30% Hypokalemia 9% 13% Pyrexia 7% 2% Agitation 7% 6% Hyperglycemia 7% 2% Constipation 6% 6% Hypoglycemia 5% 6% Respiratory Failure 5% 3% Renal Failure Acute 2% 1% Acute Respiratory Distress Syndrome 2% 1% Generalized Edema 2% 6% Hypomagnesemia 1% 7% The following adverse events occurred between 2 and 5% for Dexmedetomidine Hydrochloride and Midazolam, respectively: renal failure acute (2.5%, 0.8%), acute respiratory distress syndrome (2.5%, 0.8%), and respiratory failure (4.5%, 3.3%). Table 6: Number (%) of Adult Subjects Who Had a Dose-Related Increase in Treatment Emergent Adverse Events by Maintenance Adjusted Dose Rate Range in the Dexmedetomidine Hydrochloride Group * Average maintenance dose over the entire study drug administration. Dexmedetomidine Hydrochloride (mcg/kg/hr) Adverse Event ≤0.7* (N = 95) >0.7 to ≤1.1* (N = 78) >1.1* (N = 71) Constipation 6% 5% 14% Agitation 5% 8% 14% Anxiety 5% 5% 9% Edema Peripheral 3% 5% 7% Atrial Fibrillation 2% 4% 9% Respiratory Failure 2% 6% 10% Acute Respiratory Distress Syndrome 1% 3% 9% Adult Procedural Sedation Adverse reaction information is derived from the two trials for adult procedural sedation [see Clinical Studies ( 14.2 )] in which 318 adult patients received Dexmedetomidine Injection. The mean total dose was 1.6 mcg/kg (range: 0.5 to 6.7), mean dose per hour was 1.3 mcg/kg/hr (range: 0.3 to 6.1) and the mean duration of infusion of 1.5 hours (range: 0.1 to 6.2). The population was between 18 to 93 years of age, ASA I-IV, 30% ≥65 years of age, 52% male and 61% Caucasian. Treatment-emergent adverse reactions occurring in adults at an incidence of >2% are provided in Table 7 . The most frequent adverse reactions were hypotension, bradycardia, and dry mouth [see Warnings and Precautions ( 5.2 )] . Pre-specified criteria for the vital signs to be reported as adverse reactions are footnoted below the table. The decrease in respiratory rate and hypoxia was similar between Dexmedetomidine Injection and comparator groups in both studies. Table 7: Adverse Reactions with an Incidence >2%-Adult Procedural Sedation Population 1 Hypotension was defined in absolute and relative terms as Systolic blood pressure of <80 mmHg or ≤30% lower than pre-study drug infusion value, or Diastolic blood pressure of <50 mmHg. 2 Respiratory depression was defined in absolute and relative terms as respiratory rate (RR) <8 beats per minute or >25% decrease from baseline. 3 Bradycardia was defined in absolute and relative terms as <40 beats per minute or ≤30% lower than pre-study drug infusion value. Subjects in Study 2 were pretreated with glycopyrrolate 0.1 mg intravenously before receiving study drug [see Clinical Studies ( 14.2 )]. 4 Hypertension was defined in absolute and relative terms as Systolic blood pressure >180 mmHg or ≥30% higher than pre-study drug infusion value or Diastolic blood pressure of >100 mmHg. 5 Tachycardia was defined in absolute and relative terms as >120 beats per minute or ≥30% greater than pre-study drug infusion value. 6 Hypoxia was defined in absolute and relative terms as S p O 2 <90% or 10% decrease from baseline. Adverse Event Dexmedetomidine Hydrochloride (N = 318) (%) Placebo (N = 113) (%) Hypotension 1 54% 30% Respiratory Depression 2 37% 32% Bradycardia 3 14% 4% Hypertension 4 13% 24% Tachycardia 5 5% 17% Nausea 3% 2% Dry Mouth 3% 1% Hypoxia 6 2% 3% Bradypnea 2% 4% Pediatric use information is approved for Hospira Inc.'s PRECEDEX TM (dexmedetomidine hydrochloride) injection. However, due to Hospira Inc.'s marketing exclusivity rights, this drug product is not labeled with that information. 6.2 Postmarketing Experience The following adverse reactions have been identified during post-approval use of Dexmedetomidine Injection. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Hypotension and bradycardia were the most common adverse reactions associated with the use of Dexmedetomidine Injection during post-approval use of the drug. Table 9: Adverse Reactions Experienced During Post-Approval Use of Dexmedetomidine Hydrochloride System Organ Class Preferred Term Blood and Lymphatic System Disorders Anemia Cardiac Disorders Arrhythmia, atrial fibrillation, atrioventricular block, bradycardia, cardiac arrest, cardiac disorder, extrasystoles, myocardial infarction, supraventricular tachycardia, tachycardia, ventricular arrhythmia, ventricular tachycardia Eye Disorders Photopsia, visual impairment Gastrointestinal Disorders Abdominal pain, diarrhea, nausea, vomiting General Disorders and Administration Site Conditions Chills, hyperpyrexia, pain, pyrexia, thirst Hepatobiliary Disorders Hepatic function abnormal, hyperbilirubinemia Investigations Alanine aminotransferase increased, aspartate aminotransferase increased, blood alkaline phosphatase increased, blood urea increased, electrocardiogram T wave inversion, gammaglutamyltransferase increased, electrocardiogram QT prolonged Metabolism and Nutrition Disorders Acidosis, hyperkalemia, hypoglycemia, hypovolemia, hypernatremia Nervous System Disorders Convulsion, dizziness, headache, neuralgia, neuritis, speech disorder Psychiatric Disorders Agitation, confusional state, delirium, hallucination, illusion Renal and Urinary Disorders Oliguria, polyuria Respiratory, Thoracic and Mediastinal Disorders Apnea, bronchospasm, dyspnea, hypercapnia, hypoventilation, hypoxia, pulmonary congestion, respiratory acidosis Skin and Subcutaneous Tissue Disorders Hyperhidrosis, pruritus, rash, urticaria Surgical and Medical Procedures Light anesthesia Vascular Disorders Blood pressure fluctuation, hemorrhage, hypertension, hypotension"],"contraindications":["4 CONTRAINDICATIONS None. None. ( 4 )"],"drug_interactions":["7 DRUG INTERACTIONS Anesthetics, Sedatives, Hypnotics, Opioids: Enhancement of pharmacodynamic effects. Reduction in dosage of dexmedetomidine hydrochloride or the concomitant medication may be required. ( 7.1 ) 7.1 Anesthetics, Sedatives, Hypnotics, Opioids Co-administration of Dexmedetomidine Injection with anesthetics, sedatives, hypnotics, and opioids is likely to lead to an enhancement of effects. Specific studies have confirmed these effects with sevoflurane, isoflurane, propofol, alfentanil, and midazolam. No pharmacokinetic interactions between Dexmedetomidine Injection and isoflurane, propofol, alfentanil and midazolam have been demonstrated. However, due to possible pharmacodynamic interactions, when co-administered with Dexmedetomidine Injection, a reduction in dosage of Dexmedetomidine Injection or the concomitant anesthetic, sedative, hypnotic or opioid may be required. 7.2 Neuromuscular Blockers In one study of 10 healthy adult volunteers, administration of Dexmedetomidine Injection for 45 minutes at a plasma concentration of one ng/mL resulted in no clinically meaningful increases in the magnitude of neuromuscular blockade associated with rocuronium administration."],"how_supplied_table":["<table width=\"100%\"><col width=\"25%\"/><col width=\"25%\"/><col width=\"25%\"/><col width=\"25%\"/><tbody><tr><td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Product Code</content></paragraph></td><td styleCode=\"Rrule Botrule Toprule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Unit of Sale</content> </paragraph></td><td styleCode=\"Rrule Botrule Toprule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Strength</content> </paragraph></td><td styleCode=\"Rrule Botrule Toprule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Each</content> </paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>RF462102</paragraph></td><td styleCode=\"Rrule Toprule Botrule \" valign=\"top\"><paragraph>NDC 65219-642-02 Unit of 25 </paragraph></td><td styleCode=\"Rrule Toprule Botrule \" valign=\"top\"><paragraph>200 mcg (dexmedetomidine) per 2 mL (100 mcg (dexmedetomidine) per mL)</paragraph></td><td styleCode=\"Rrule Toprule Botrule \" valign=\"top\"><paragraph>NDC 65219-642-01</paragraph><paragraph>2 mL single-dose glass vial This product is RFID-enabled.</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Toprule \" valign=\"top\"><paragraph>462102</paragraph></td><td styleCode=\"Rrule Toprule \" valign=\"top\"><paragraph>NDC 63323-421-02 Unit of 25 </paragraph></td><td styleCode=\"Rrule Toprule \" valign=\"top\"><paragraph>200 mcg (dexmedetomidine) per 2 mL (100 mcg (dexmedetomidine) per mL) </paragraph></td><td styleCode=\"Rrule Toprule \" valign=\"top\"><paragraph>NDC 63323-421-01</paragraph><paragraph>2 mL single-dose glass vial </paragraph></td></tr><tr><td styleCode=\"Rrule Botrule Lrule \" valign=\"top\"/><td styleCode=\"Rrule Botrule \" valign=\"top\"/><td styleCode=\"Rrule Botrule \" valign=\"top\"/><td styleCode=\"Rrule Botrule \" valign=\"top\"/></tr></tbody></table>"],"mechanism_of_action":["12.1 Mechanism of Action Dexmedetomidine Injection is a relatively selective centrally acting alpha 2 -adrenergic agonist with sedative properties. Alpha 2 selectivity is observed in animals following slow intravenous infusion of low and medium doses (10-300 mcg/kg). Both alpha 1 and alpha 2 activity is observed following slow intravenous infusion of high doses (≥1,000 mcg/kg) or with rapid intravenous administration."],"controlled_substance":["9.1 Controlled Substance Dexmedetomidine Hydrochloride is not a controlled substance."],"recent_major_changes":["Dosage and Administration, Preparation of Solution ( 2.4 ) 08/2022 Warnings and Precautions, Hyperthermia or Pyrexia ( 5.7 ) 08/2022"],"clinical_pharmacology":["12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action Dexmedetomidine Injection is a relatively selective centrally acting alpha 2 -adrenergic agonist with sedative properties. Alpha 2 selectivity is observed in animals following slow intravenous infusion of low and medium doses (10-300 mcg/kg). Both alpha 1 and alpha 2 activity is observed following slow intravenous infusion of high doses (≥1,000 mcg/kg) or with rapid intravenous administration. 12.2 Pharmacodynamics In a study in healthy adult volunteers (N = 10), respiratory rate and oxygen saturation remained within normal limits and there was no evidence of respiratory depression when Dexmedetomidine Injection was administered by intravenous infusion at doses within the recommended dose range (0.2-0.7 mcg/kg/hr). 12.3 Pharmacokinetics Following intravenous administration to adults, dexmedetomidine exhibits the following pharmacokinetic parameters: a rapid distribution phase with a distribution half-life (t 1/2 ) of approximately 6 minutes; a terminal elimination half-life (t 1/2 ) of approximately 2 hours; and steady-state volume of distribution (V ss ) of approximately 118 liters. Clearance is estimated to be approximately 39 L/h. The mean body weight associated with this clearance estimate was 72 kg. Dexmedetomidine exhibits linear pharmacokinetics in the dosage range of 0.2 to 0.7 mcg/kg/hr when administered to adults by intravenous infusion for up to 24 hours. Table 10 shows the main pharmacokinetic parameters when Dexmedetomidine Injection was infused (after appropriate loading doses) at maintenance infusion rates of 0.17 mcg/kg/hr (target plasma concentration of 0.3 ng/mL) for 12 and 24 hours, 0.33 mcg/kg/hr (target plasma concentration of 0.6 ng/mL) for 24 hours, and 0.70 mcg/kg/hr (target plasma concentration of 1.25 ng/mL) for 24 hours. Table 10: Mean ± SD Pharmacokinetic Parameters in Adults Abbreviations: t 1/2 = half-life, CL = clearance, V ss = steady-state volume of distribution. * Presented as harmonic mean and pseudo standard deviation. # Mean C ss = Average steady-state concentration of Dexmedetomidine Injection. The mean C ss was calculated based on post-dose sampling from 2.5 to 9 hours samples for 12 hour infusion and post-dose sampling from 2.5 to 18 hours for 24 hour infusions. Parameter Loading Infusion (min)/Total Infusion Duration (hrs) 10 min/12 hrs 10 min/24 hrs 10 min/24 hrs 35 min/24 hrs Dexmedetomidine Target Plasma Concentration (ng/mL) and Dose (mcg/kg/hr) 0.3/0.17 0.3/0.17 0.6/0.33 1.25/0.70 t 1/2 *, hour 1.78 ± 0.30 2.22 ± 0.59 2.23 ± 0.21 2.50 ± 0.61 CL, liter/hour 46.3 ± 8.3 43.1 ± 6.5 35.3 ± 6.8 36.5 ± 7.5 V ss , liter 88.7 ± 22.9 102.4 ± 20.3 93.6 ± 17.0 99.6 ± 17.8 Avg C ss # , ng/mL 0.27 ± 0.05 0.27 ± 0.05 0.67 ± 0.10 1.37 ± 0.20 The loading doses for each of the above indicated groups were 0.5, 0.5, 1 and 2.2 mcg/kg, respectively. Dexmedetomidine pharmacokinetic parameters in adults after Dexmedetomidine Injection maintenance doses of 0.2 to 1.4 mcg/kg/hr for >24 hours were similar to the pharmacokinetic (PK) parameters after Dexmedetomidine Injection maintenance dosing for <24 hours in other studies. The values for clearance (CL), volume of distribution (V), and t 1/2 were 39.4 L/hr, 152 L, and 2.67 hours, respectively. Distribution The steady-state volume of distribution (V ss ) of dexmedetomidine was approximately 118 liters. Dexmedetomidine protein binding was assessed in the plasma of normal healthy male and female subjects. The average protein binding was 94% and was constant across the different plasma concentrations tested. Protein binding was similar in males and females. The fraction of Dexmedetomidine Injection that was bound to plasma proteins was significantly decreased in subjects with hepatic impairment compared to healthy subjects. The potential for protein binding displacement of dexmedetomidine by fentanyl, ketorolac, theophylline, digoxin and lidocaine was explored in vitro , and negligible changes in the plasma protein binding of Dexmedetomidine Injection were observed. The potential for protein binding displacement of phenytoin, warfarin, ibuprofen, propranolol, theophylline and digoxin by Dexmedetomidine Injection was explored in vitro and none of these compounds appeared to be significantly displaced by Dexmedetomidine Injection. Elimination Metabolism Dexmedetomidine undergoes almost complete biotransformation with very little unchanged dexmedetomidine excreted in urine and feces. Biotransformation involves both direct glucuronidation as well as cytochrome P450 mediated metabolism. The major metabolic pathways of dexmedetomidine are: direct N-glucuronidation to inactive metabolites; aliphatic hydroxylation (mediated primarily by CYP2A6 with a minor role of CYP1A2, CYP2E1, CYP2D6 and CYP2C19) of dexmedetomidine to generate 3-hydroxy-dexmedetomidine, the glucuronide of 3-hydroxy-dexmedetomidine, and 3-carboxy-dexmedetomidine; and N-methylation of dexmedetomidine to generate 3-hydroxy N-methyl-dexmedetomidine, 3-carboxy N-methyl-dexmedetomidine, and dexmedetomidine-N-methyl O- glucuronide. Excretion The terminal elimination half-life (t 1/2 ) of dexmedetomidine is approximately 2 hours and clearance is estimated to be approximately 39 L/h. A mass balance study demonstrated that after nine days an average of 95% of the radioactivity, following intravenous administration of radiolabeled dexmedetomidine, was recovered in the urine and 4% in the feces. No unchanged dexmedetomidine was detected in the urine. Approximately 85% of the radioactivity recovered in the urine was excreted within 24 hours after the infusion. Fractionation of the radioactivity excreted in urine demonstrated that products of N-glucuronidation accounted for approximately 34% of the cumulative urinary excretion. In addition, aliphatic hydroxylation of parent drug to form 3-hydroxy-dexmedetomidine, the glucuronide of 3-hydroxy-dexmedetomidine, and 3-carboxylic acid-dexmedetomidine together represented approximately 14% of the dose in urine. N-methylation of dexmedetomidine to form 3-hydroxy N-methyl dexmedetomidine, 3-carboxy N-methyl dexmedetomidine, and N-methyl O-glucuronide dexmedetomidine accounted for approximately 18% of the dose in urine. The N-Methyl metabolite itself was a minor circulating component and was undetected in urine. Approximately 28% of the urinary metabolites have not been identified. Specific Populations Male and Female Patients There was no observed difference in Dexmedetomidine Injection pharmacokinetics due to sex. Geriatric Patients The pharmacokinetic profile of Dexmedetomidine Injection was not altered by age. There were no differences in the pharmacokinetics of Dexmedetomidine Injection in young (18-40 years), middle age (41-65 years), and elderly (>65 years) subjects. Pediatric Patients Pediatric use information is approved for Hospira Inc.'s PRECEDEX TM (dexmedetomidine hydrochloride) injection. However, due to Hospira Inc.'s marketing exclusivity rights, this drug product is not labeled with that information. Patients with Hepatic Impairment In adult subjects with varying degrees of hepatic impairment (Child-Pugh Class A, B, or C), clearance values for Dexmedetomidine Injection were lower than in healthy subjects. The mean clearance values for patients with mild, moderate, and severe hepatic impairment were 74%, 64% and 53% of those observed in the normal healthy adult subjects, respectively. Mean clearances for free drug were 59%, 51% and 32% of those observed in the normal healthy adult subjects, respectively. Although Dexmedetomidine Injection is dosed to effect, it may be necessary to consider dose reduction in subjects with hepatic impairment [see Dosage and Administration ( 2.2 ), Warnings and Precautions ( 5.8 )] . Patients with Renal Impairment Dexmedetomidine Injection pharmacokinetics (C max , T max , AUC, t 1/2 , CL, and V ss ) were not significantly different in patients with severe renal impairment (creatinine clearance: <30 mL/min) compared to healthy subjects. Drug Interaction Studies In vitro studies: In vitro studies in human liver microsomes demonstrated no evidence of cytochrome P450 mediated drug interactions that are likely to be of clinical relevance."],"indications_and_usage":["1 INDICATIONS AND USAGE Dexmedetomidine hydrochloride is a alpha 2 -adrenergic receptor agonist indicated for: • Sedation of initially intubated and mechanically ventilated adult patients during treatment in an intensive care setting. Administer dexmedetomidine hydrochloride by continuous infusion not to exceed 24 hours. ( 1.1 ) • Sedation of non-intubated adult patients prior to and/or during surgical and other procedures. ( 1.2 ) 1.1 Intensive Care Unit Sedation Dexmedetomidine Injection is indicated for sedation of initially intubated and mechanically ventilated adult patients during treatment in an intensive care setting. Dexmedetomidine Injection should be administered by continuous infusion not to exceed 24 hours. Dexmedetomidine Injection has been continuously infused in mechanically ventilated adult patients prior to extubation, during extubation, and post-extubation. It is not necessary to discontinue Dexmedetomidine Injection prior to extubation. 1.2 Procedural Sedation Dexmedetomidine Injection is indicated for sedation of non-intubated adult patients prior to and/or during surgical and other procedures. Pediatric use information is approved for Hospira Inc.'s PRECEDEX TM (dexmedetomidine hydrochloride) injection. However, due to Hospira Inc.'s marketing exclusivity rights, this drug product is not labeled with that information."],"warnings_and_cautions":["5 WARNINGS AND PRECAUTIONS • Monitoring : Continuously monitor patients while receiving dexmedetomidine hydrochloride. ( 5.1 ) • Bradycardia and Sinus Arrest : Have occurred in young healthy volunteers with high vagal tone or with different routes of administration, e.g., rapid intravenous or bolus administration. ( 5.2 ) • Hypotension and Bradycardia : May necessitate medical intervention. May be more pronounced in patients with hypovolemia, diabetes mellitus, or chronic hypertension, and in the elderly. Use with caution in patients with advanced heart block or severe ventricular dysfunction. ( 5.2 ) • Co-administration with Other Vasodilators or Negative Chronotropic Agents : Use with caution due to additive pharmacodynamic effects. ( 5.2 ) • Transient Hypertension : Observed primarily during the loading dose. Consider reduction in loading infusion rate. ( 5.3 ) • Arousability : Patients can become aroused/alert with stimulation; this alone should not be considered as lack of efficacy. ( 5.4 ) • Tolerance and Tachyphylaxis : Prolonged exposure to dexmedetomidine beyond 24 hours may be associated with tolerance and tachyphylaxis and a dose-related increase in adverse events. ( 5.6 ) 5.1 Drug Administration Dexmedetomidine Injection should be administered only by persons skilled in the management of patients in the intensive care or operating room setting. Due to the known pharmacological effects of Dexmedetomidine Injection, patients should be continuously monitored while receiving Dexmedetomidine Injection. 5.2 Hypotension, Bradycardia, and Sinus Arrest Clinically significant episodes of bradycardia and sinus arrest have been reported with Dexmedetomidine Injection administration in young, healthy adult volunteers with high vagal tone or with different routes of administration including rapid intravenous or bolus administration. Reports of hypotension and bradycardia have been associated with Dexmedetomidine Injection infusion. Some of these cases have resulted in fatalities. If medical intervention is required, treatment may include decreasing or stopping the infusion of Dexmedetomidine Injection, increasing the rate of intravenous fluid administration, elevation of the lower extremities, and use of pressor agents. Because Dexmedetomidine Injection has the potential to augment bradycardia induced by vagal stimuli, clinicians should be prepared to intervene. The intravenous administration of anticholinergic agents (e.g., glycopyrrolate, atropine) should be considered to modify vagal tone. In clinical trials, glycopyrrolate or atropine were effective in the treatment of most episodes of Dexmedetomidine Injection-induced bradycardia. However, in some patients with significant cardiovascular dysfunction, more advanced resuscitative measures were required. Caution should be exercised when administering Dexmedetomidine Injection to patients with advanced heart block and/or severe ventricular dysfunction. Because Dexmedetomidine Injection decreases sympathetic nervous system activity, hypotension and/or bradycardia may be expected to be more pronounced in patients with hypovolemia, diabetes mellitus, or chronic hypertension and in elderly patients. In clinical trials where other vasodilators or negative chronotropic agents were co-administered with Dexmedetomidine Injection an additive pharmacodynamic effect was not observed. Nonetheless, caution should be used when such agents are administered concomitantly with Dexmedetomidine Injection. 5.3 Transient Hypertension Transient hypertension has been observed primarily during the loading dose in association with the initial peripheral vasoconstrictive effects of Dexmedetomidine Injection. Treatment of the transient hypertension has generally not been necessary, although reduction of the loading infusion rate may be desirable. 5.4 Arousability Some patients receiving Dexmedetomidine Injection have been observed to be arousable and alert when stimulated. This alone should not be considered as evidence of lack of efficacy in the absence of other clinical signs and symptoms. 5.5 Withdrawal Intensive Care Unit Sedation With administration up to 7 days, regardless of dose, 12 (5%) Dexmedetomidine Injection adult subjects experienced at least 1 event related to withdrawal within the first 24 hours after discontinuing study drug and 7 (3%) Dexmedetomidine Injection adult subjects experienced at least 1 event 24 to 48 hours after end of study drug. The most common events were nausea, vomiting, and agitation [see Adverse Reactions ( 6.1 )]. In adult subjects, tachycardia and hypertension requiring intervention in the 48 hours following study drug discontinuation occurred at frequencies of ˂5%. Procedural Sedation In adult subjects, withdrawal symptoms were not seen after discontinuation of short-term infusions of Dexmedetomidine Injection (<6 hours). In pediatric patients, mild transient withdrawal symptoms of emergence delirium or agitation were seen after discontinuation of short-term infusions of Dexmedetomidine Injection (<2 hours). Pediatric use information is approved for Hospira Inc.'s PRECEDEX TM (dexmedetomidine hydrochloride) injection. However, due to Hospira Inc.'s marketing exclusivity rights, this drug product is not labeled with that information. 5.6 Tolerance and Tachyphylaxis Use of dexmedetomidine beyond 24 hours has been associated with tolerance and tachyphylaxis and a dose-related increase in adverse reactions [see Adverse Reactions ( 6.1 )] . 5.7 Hyperthermia or Pyrexia Dexmedetomidine Injection may induce hyperthermia or pyrexia, which may be resistant to traditional cooling methods, such as administration of cooled intravenous fluids and antipyretic medications. Discontinue Dexmedetomidine Injection if drug-related hyperthermia or pyrexia is suspected and monitor patients until body temperature normalizes. 5.8 Hepatic Impairment Since Dexmedetomidine Injection clearance decreases with severity of hepatic impairment, dose reduction should be considered in patients with impaired hepatic function [see Dosage and Administration ( 2.2 , 2.3 )] ."],"clinical_studies_table":["<table ID=\"_Reft12\" width=\"100%\"><caption>Table 12: Ramsay Level of Sedation Scale </caption><col width=\"21%\"/><col width=\"79%\"/><tbody><tr><td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Clinical Score</content></paragraph></td><td styleCode=\"Rrule Botrule Toprule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Level of Sedation Achieved</content></paragraph></td></tr><tr><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>6 </paragraph></td><td styleCode=\"Rrule Botrule \" valign=\"top\"><paragraph>Asleep, no response </paragraph></td></tr><tr><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>5 </paragraph></td><td styleCode=\"Rrule Botrule \" valign=\"top\"><paragraph>Asleep, sluggish response to light glabellar tap or loud auditory stimulus </paragraph></td></tr><tr><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>4 </paragraph></td><td styleCode=\"Rrule Botrule \" valign=\"top\"><paragraph>Asleep, but with brisk response to light glabellar tap or loud auditory stimulus </paragraph></td></tr><tr><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>3 </paragraph></td><td styleCode=\"Rrule Botrule \" valign=\"top\"><paragraph>Patient responds to commands </paragraph></td></tr><tr><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>2 </paragraph></td><td styleCode=\"Rrule Botrule \" valign=\"top\"><paragraph>Patient cooperative, oriented, and tranquil </paragraph></td></tr><tr><td align=\"center\" styleCode=\"Rrule Botrule Lrule \" valign=\"top\"><paragraph>1 </paragraph></td><td styleCode=\"Rrule Botrule \" valign=\"top\"><paragraph>Patient anxious, agitated, or restless </paragraph></td></tr></tbody></table>","<table ID=\"_Reft13\" width=\"100%\"><caption>Table 13: Midazolam Use as Rescue Medication During Intubation (ITT) Study One </caption><col width=\"25%\"/><col width=\"25%\"/><col width=\"25%\"/><col width=\"25%\"/><tfoot><tr><td align=\"left\" colspan=\"4\" valign=\"top\">ITT (intent-to-treat) population includes all randomized patients. </td></tr><tr><td align=\"left\" colspan=\"4\" valign=\"top\">* ANOVA model with treatment center. </td></tr><tr><td align=\"left\" colspan=\"4\" valign=\"top\">** Chi-square. </td></tr></tfoot><tbody><tr><td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"/><td align=\"center\" styleCode=\"Rrule Botrule Toprule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Placebo </content> <content styleCode=\"bold\">(N=175)</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Toprule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Dexmedetomidine hydrochloride </content> <content styleCode=\"bold\">(N=178)</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Toprule \" valign=\"top\"><paragraph><content styleCode=\"bold\">p-value</content></paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Mean Total Dose (mg) of Midazolam</content>  Standard deviation </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"top\"><paragraph>19 mg 53 mg </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"top\"><paragraph>5 mg 19 mg </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"top\"><paragraph>0.0011* </paragraph></td></tr><tr><td colspan=\"4\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Categorized Midazolam Use</content></paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph> 0 mg </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"top\"><paragraph>43 (25%) </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"top\"><paragraph>108 (61%) </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"top\"><paragraph>&#x2C2;0.001** </paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph> 0-4 mg </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"top\"><paragraph>34 (19%) </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"top\"><paragraph>36 (20%) </paragraph></td><td styleCode=\"Rrule Botrule \" valign=\"top\"/></tr><tr><td styleCode=\"Rrule Botrule Lrule \" valign=\"top\"><paragraph> &#x2C3;4 mg </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"top\"><paragraph>98 (56%) </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"top\"><paragraph>34 (19%) </paragraph></td><td styleCode=\"Rrule Botrule \" valign=\"top\"/></tr></tbody></table>","<table ID=\"_Reft14\" width=\"100%\"><caption>Table 14: Propofol Use as Rescue Medication During Intubation (ITT) Study Two </caption><col width=\"30%\"/><col width=\"22%\"/><col width=\"23%\"/><col width=\"25%\"/><tfoot><tr><td align=\"left\" colspan=\"4\" valign=\"top\">* ANOVA model with treatment center. </td></tr><tr><td align=\"left\" colspan=\"4\" valign=\"top\">** Chi-square. </td></tr></tfoot><tbody><tr><td styleCode=\"Rrule Botrule Toprule \" valign=\"top\"/><td align=\"center\" styleCode=\"Rrule Botrule Toprule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Placebo</content> <content styleCode=\"bold\">(N = 198)</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Toprule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Dexmedetomidine Hydrochloride</content> <content styleCode=\"bold\">(N =203)</content></paragraph></td><td align=\"center\" styleCode=\"Botrule Toprule \" valign=\"top\"><paragraph> <content styleCode=\"bold\">p-value</content></paragraph></td></tr><tr><td styleCode=\"Rrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Mean Total Dose (mg) of Propofol</content>  Standard deviation </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"top\"><paragraph>513 mg 782 mg </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"top\"><paragraph>72 mg 249 mg </paragraph></td><td align=\"center\" styleCode=\"Botrule \" valign=\"top\"><paragraph>&lt;0.0001* </paragraph></td></tr><tr><td colspan=\"4\" styleCode=\"Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Categorized Propofol Use</content></paragraph></td></tr><tr><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"top\"><paragraph>0 mg </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"top\"><paragraph>47 (24%) </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"top\"><paragraph>122 (60%) </paragraph></td><td align=\"center\" styleCode=\"Botrule \" valign=\"top\"><paragraph>&lt;0.001** </paragraph></td></tr><tr><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"top\"><paragraph>0&#x2013;50 mg </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"top\"><paragraph>30 (15%) </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"top\"><paragraph>43 (21%) </paragraph></td><td styleCode=\"Botrule \" valign=\"top\"/></tr><tr><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"top\"><paragraph>&gt;50 mg </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"top\"><paragraph>121 (61%) </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"top\"><paragraph>38 (19%) </paragraph></td><td styleCode=\"Botrule \" valign=\"top\"/></tr></tbody></table>","<table ID=\"_Reft15\" width=\"100%\"><caption>Table 15: Observer&apos;s Assessment of Alertness/Sedation </caption><col width=\"20%\"/><col width=\"20%\"/><col width=\"20%\"/><col width=\"20%\"/><col width=\"20%\"/><tbody><tr><td align=\"center\" colspan=\"5\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Assessment Categories</content></paragraph></td></tr><tr><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Responsiveness</content> </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Speech</content> </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Facial Expression</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Eyes</content> </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Composite Score</content> </paragraph></td></tr><tr><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>Responds readily to name spoken in normal tone </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"top\"><paragraph>Normal </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"top\"><paragraph>Normal </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"top\"><paragraph>Clear, no ptosis </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"top\"><paragraph>5 (alert) </paragraph></td></tr><tr><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>Lethargic response to name spoken in normal tone </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"top\"><paragraph>Mild slowing or thickening </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"top\"><paragraph>Mild relaxation </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"top\"><paragraph>Glazed or mild ptosis (less than half the eye) </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"top\"><paragraph>4 </paragraph></td></tr><tr><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>Responds only after name is called loudly and/or repeatedly </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"top\"><paragraph>Slurring or prominent slowing </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"top\"><paragraph>Marked relaxation (slack jaw) </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"top\"><paragraph>Glazed and marked ptosis (half the eye or more) </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"top\"><paragraph>3 </paragraph></td></tr><tr><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>Responds only after mild prodding or shaking </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"top\"><paragraph>Few recognizable words </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"top\"><paragraph>- </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"top\"><paragraph>- </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"top\"><paragraph>2 </paragraph></td></tr><tr><td align=\"center\" styleCode=\"Rrule Botrule Lrule \" valign=\"top\"><paragraph>Does not respond to mild prodding or shaking </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"top\"><paragraph>- </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"top\"><paragraph>- </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"top\"><paragraph>- </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"top\"><paragraph>1 (deep sleep) </paragraph></td></tr></tbody></table>","<table ID=\"_Reft16\" width=\"100%\"><caption>Table 16: Key Efficacy Results of Adult Procedural Sedation Studies </caption><col width=\"9%\"/><col width=\"18%\"/><col width=\"18%\"/><col width=\"13%\"/><col width=\"14%\"/><col width=\"14%\"/><col width=\"14%\"/><tfoot><tr><td align=\"left\" colspan=\"7\" valign=\"top\"><sup>a</sup> Based on ITT population defined as all randomized and treated patients. </td></tr><tr><td align=\"left\" colspan=\"7\" valign=\"top\"><sup>b</sup> Normal approximation to the binomial with continuity correction. </td></tr></tfoot><tbody><tr><td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph> <content styleCode=\"bold\">Study</content></paragraph></td><td styleCode=\"Rrule Botrule Toprule \" valign=\"top\"><paragraph>  <content styleCode=\"bold\">Loading Infusion Treatment Arm</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Toprule \" valign=\"top\"><paragraph>  <content styleCode=\"bold\">Number of Patients Enrolled<sup>a</sup></content></paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Toprule \" valign=\"top\"><paragraph>  <content styleCode=\"bold\">% Not Requiring Midazolam Rescue</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Toprule \" valign=\"top\"><paragraph> <content styleCode=\"bold\">Confidence<sup>b </sup>Interval on the Difference vs. Placebo</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Toprule \" valign=\"top\"><paragraph> <content styleCode=\"bold\">Mean (SD) Total Dose (mg) of Rescue Midazolam Required</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Toprule \" valign=\"top\"><paragraph> <content styleCode=\"bold\">Confidence<sup>b</sup> Intervals of the Mean Rescue Dose</content></paragraph></td></tr><tr><td styleCode=\"Rrule Lrule \" valign=\"top\"/><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"top\"><paragraph>Dexmedetomidine 0.5 mcg/kg </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"top\"><paragraph>134 </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"top\"><paragraph>40 </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"top\"><paragraph>37 (27, 48) </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"top\"><paragraph>1.4 (1.7) </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"top\"><paragraph>-2.7 (-3.4, -2.0) </paragraph></td></tr><tr><td styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Study 1</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"top\"><paragraph>Dexmedetomidine 1 mcg/kg </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"top\"><paragraph>129 </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"top\"><paragraph>54 </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"top\"><paragraph>51 (40, 62) </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"top\"><paragraph>0.9 (1.5) </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"top\"><paragraph>-3.1 (-3.8, -2.5) </paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"/><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"top\"><paragraph>Placebo </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"top\"><paragraph>63 </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"top\"><paragraph>3 </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"top\"><paragraph>&#x2013; </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"top\"><paragraph>4.1 (3.0) </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"top\"><paragraph>&#x2013; </paragraph></td></tr><tr><td rowspan=\"2\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph> <content styleCode=\"bold\">Study 2</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"top\"><paragraph>Dexmedetomidine 1 mcg/kg </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"top\"><paragraph>55 </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"top\"><paragraph>53 </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"top\"><paragraph>39 (20, 57) </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"top\"><paragraph>1.1 (1.5) </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"top\"><paragraph>-1.8 (-2.7, -0.9) </paragraph></td></tr><tr><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"top\"><paragraph>Placebo </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"top\"><paragraph>50 </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"top\"><paragraph>14 </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"top\"><paragraph>&#x2013; </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"top\"><paragraph>2.9 (3.0) </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"top\"><paragraph>&#x2013; </paragraph></td></tr></tbody></table>"],"nonclinical_toxicology":["13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility Carcinogenesis Animal carcinogenicity studies have not been performed with dexmedetomidine. Mutagenesis Dexmedetomidine was not mutagenic in vitro , in either the bacterial reverse mutation assay ( E. coli and Salmonella typhimurium ) or the mammalian cell forward mutation assay (mouse lymphoma). Dexmedetomidine was clastogenic in the in vitro human lymphocyte chromosome aberration test with, but not without, rat S9 metabolic activation. In contrast, dexmedetomidine was not clastogenic in the in vitro human lymphocyte chromosome aberration test with or without human S9 metabolic activation. Although dexmedetomidine was clastogenic in an in vivo mouse micronucleus test in NMRI mice, there was no evidence of clastogenicity in CD-1 mice. Impairment of Fertility Fertility in male or female rats was not affected after daily subcutaneous injections of dexmedetomidine at doses up to 54 mcg/kg (less than the maximum recommended human intravenous dose on a mcg/m 2 basis) administered from 10 weeks prior to mating in males, and 3 weeks prior to mating and during mating in females. 13.2 Animal Toxicology and/or Pharmacology There were no differences in the adrenocorticotropic hormone (ACTH)-stimulated cortisol response in dogs following a single dose of dexmedetomidine compared to saline control. However, after continuous subcutaneous infusions of dexmedetomidine at 3 mcg/kg/hr and 10 mcg/kg/hr for one week in dogs (exposures estimated to be within the clinical range), the ACTH-stimulated cortisol response was diminished by approximately 27% and 40%, respectively, compared to saline-treated control animals indicating a dose-dependent adrenal suppression."],"pharmacokinetics_table":["<table ID=\"_Reft10\" width=\"100%\"><caption>Table 10: Mean &#xB1; SD Pharmacokinetic Parameters in Adults </caption><col width=\"17%\"/><col width=\"21%\"/><col width=\"21%\"/><col width=\"21%\"/><col width=\"21%\"/><tfoot><tr><td align=\"left\" colspan=\"5\" valign=\"top\">Abbreviations: t<sub>1/2</sub> = half-life, CL = clearance, V<sub>ss</sub> = steady-state volume of distribution. </td></tr><tr><td align=\"left\" colspan=\"5\" valign=\"top\">* Presented as harmonic mean and pseudo standard deviation. </td></tr><tr><td align=\"left\" colspan=\"5\" valign=\"top\"><sup>#</sup> Mean C<sub>ss</sub> = Average steady-state concentration of Dexmedetomidine Injection. The mean C<sub>ss</sub> was calculated based on post-dose sampling from 2.5 to 9 hours samples for 12 hour infusion and post-dose sampling from 2.5 to 18 hours for 24 hour infusions. </td></tr></tfoot><tbody><tr><td rowspan=\"4\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"bottom\"><paragraph><content styleCode=\"bold\">Parameter</content> </paragraph></td><td align=\"center\" colspan=\"4\" styleCode=\"Rrule Botrule Toprule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Loading Infusion (min)/Total Infusion Duration (hrs)</content> </paragraph></td></tr><tr><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">10 min/12 hrs</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">10 min/24 hrs</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">10 min/24 hrs</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">35 min/24 hrs</content></paragraph></td></tr><tr><td align=\"center\" colspan=\"4\" styleCode=\"Rrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Dexmedetomidine Target Plasma Concentration (ng/mL) and Dose (mcg/kg/hr)</content></paragraph></td></tr><tr><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">0.3/0.17</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">0.3/0.17</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">0.6/0.33</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">1.25/0.70</content></paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">t<sub>1/2</sub>*, hour</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"top\"><paragraph>1.78 &#xB1; 0.30 </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"top\"><paragraph>2.22 &#xB1; 0.59 </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"top\"><paragraph>2.23 &#xB1; 0.21 </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"top\"><paragraph>2.50 &#xB1; 0.61 </paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">CL, liter/hour</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"top\"><paragraph>46.3 &#xB1; 8.3 </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"top\"><paragraph>43.1 &#xB1; 6.5 </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"top\"><paragraph>35.3 &#xB1; 6.8 </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"top\"><paragraph>36.5 &#xB1; 7.5 </paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">V<sub>ss</sub>, liter</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"top\"><paragraph>88.7 &#xB1; 22.9 </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"top\"><paragraph>102.4 &#xB1; 20.3 </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"top\"><paragraph>93.6 &#xB1; 17.0 </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"top\"><paragraph>99.6 &#xB1; 17.8 </paragraph></td></tr><tr><td align=\"center\" styleCode=\"Rrule Botrule Lrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Avg C<sub>ss </sub><sup>#</sup>, ng/mL</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"top\"><paragraph>0.27 &#xB1; 0.05 </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"top\"><paragraph>0.27 &#xB1; 0.05 </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"top\"><paragraph>0.67 &#xB1; 0.10 </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"top\"><paragraph>1.37 &#xB1; 0.20 </paragraph></td></tr></tbody></table>"],"adverse_reactions_table":["<table ID=\"_Reft3\" width=\"100%\"><caption>Table 3: Adverse Reactions with an Incidence &#x2C3;2%-Adult Intensive Care Unit Sedation Population &#x2C2;24 hours* </caption><col width=\"29%\"/><col width=\"19%\"/><col width=\"22%\"/><col width=\"15%\"/><col width=\"15%\"/><tfoot><tr><td align=\"left\" colspan=\"5\" valign=\"top\">* 26 subjects in the all Dexmedetomidine Hydrochloride group and 10 subjects in the randomized Dexmedetomidine Hydrochloride group had exposure for greater than 24 hours. </td></tr></tfoot><tbody><tr><td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"bottom\"><paragraph><content styleCode=\"bold\">Adverse Event</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Toprule \" valign=\"top\"><paragraph><content styleCode=\"bold\">All Dexmedetomidine Hydrochloride</content> <content styleCode=\"bold\">(N = 1007)</content> <content styleCode=\"bold\">(%)</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Toprule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Randomized Dexmedetomidine Hydrochloride</content> <content styleCode=\"bold\">(N = 798)</content> <content styleCode=\"bold\">(%)</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Toprule \" valign=\"bottom\"><paragraph><content styleCode=\"bold\">Placebo</content> <content styleCode=\"bold\">(N = 400)</content> <content styleCode=\"bold\">(%)</content> </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Toprule \" valign=\"bottom\"><paragraph><content styleCode=\"bold\">Propofol</content> <content styleCode=\"bold\">(N = 188)</content> <content styleCode=\"bold\">(%)</content> </paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>Hypotension </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"middle\"><paragraph>25% </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"middle\"><paragraph>24% </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"middle\"><paragraph>12% </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"middle\"><paragraph>13% </paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>Hypertension </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"middle\"><paragraph>12% </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"middle\"><paragraph>13% </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"middle\"><paragraph>19% </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"middle\"><paragraph>4% </paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>Nausea </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"middle\"><paragraph>9% </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"middle\"><paragraph>9% </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"middle\"><paragraph>9% </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"middle\"><paragraph>11% </paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>Bradycardia </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"middle\"><paragraph>5% </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"middle\"><paragraph>5% </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"middle\"><paragraph>3% </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"middle\"><paragraph>0 </paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>Atrial Fibrillation </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"middle\"><paragraph>4% </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"middle\"><paragraph>5% </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"middle\"><paragraph>3% </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"middle\"><paragraph>7% </paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>Pyrexia </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"middle\"><paragraph>4% </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"middle\"><paragraph>4% </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"middle\"><paragraph>4% </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"middle\"><paragraph>4% </paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>Dry Mouth </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"middle\"><paragraph>4% </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"middle\"><paragraph>3% </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"middle\"><paragraph>1% </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"middle\"><paragraph>1% </paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>Vomiting </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"middle\"><paragraph>3% </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"middle\"><paragraph>3% </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"middle\"><paragraph>5% </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"middle\"><paragraph>3% </paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>Hypovolemia </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"middle\"><paragraph>3% </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"middle\"><paragraph>3% </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"middle\"><paragraph>2% </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"middle\"><paragraph>5% </paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>Atelectasis </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"middle\"><paragraph>3% </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"middle\"><paragraph>3% </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"middle\"><paragraph>3% </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"middle\"><paragraph>6% </paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>Pleural Effusion </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"middle\"><paragraph>2% </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"middle\"><paragraph>2% </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"middle\"><paragraph>1% </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"middle\"><paragraph>6% </paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>Agitation </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"middle\"><paragraph>2% </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"middle\"><paragraph>2% </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"middle\"><paragraph>3% </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"middle\"><paragraph>1% </paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>Tachycardia </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"middle\"><paragraph>2% </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"middle\"><paragraph>2% </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"middle\"><paragraph>4% </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"middle\"><paragraph>1% </paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>Anemia </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"middle\"><paragraph>2% </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"middle\"><paragraph>2% </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"middle\"><paragraph>2% </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"middle\"><paragraph>2% </paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>Hyperthermia </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"middle\"><paragraph>2% </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"middle\"><paragraph>2% </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"middle\"><paragraph>3% </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"middle\"><paragraph>0 </paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>Chills </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"middle\"><paragraph>2% </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"middle\"><paragraph>2% </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"middle\"><paragraph>3% </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"middle\"><paragraph>2% </paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>Hyperglycemia </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"middle\"><paragraph>2% </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"middle\"><paragraph>2% </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"middle\"><paragraph>2% </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"middle\"><paragraph>3% </paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>Hypoxia </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"middle\"><paragraph>2% </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"middle\"><paragraph>2% </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"middle\"><paragraph>2% </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"middle\"><paragraph>3% </paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>Post-procedural Hemorrhage </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"middle\"><paragraph>2% </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"middle\"><paragraph>2% </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"middle\"><paragraph>3% </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"middle\"><paragraph>4% </paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>Pulmonary Edema </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"middle\"><paragraph>1% </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"middle\"><paragraph>1% </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"middle\"><paragraph>1% </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"middle\"><paragraph>3% </paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>Hypocalcemia </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"middle\"><paragraph>1% </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"middle\"><paragraph>1% </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"middle\"><paragraph>0 </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"middle\"><paragraph>2% </paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>Acidosis </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"middle\"><paragraph>1% </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"middle\"><paragraph>1% </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"middle\"><paragraph>1% </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"middle\"><paragraph>2% </paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>Urine Output Decreased </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"middle\"><paragraph>1% </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"middle\"><paragraph>1% </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"middle\"><paragraph>0 </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"middle\"><paragraph>2% </paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>Sinus Tachycardia </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"middle\"><paragraph>1% </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"middle\"><paragraph>1% </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"middle\"><paragraph>1% </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"middle\"><paragraph>2% </paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>Ventricular Tachycardia </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"middle\"><paragraph>&lt;1% </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"middle\"><paragraph>1% </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"middle\"><paragraph>1% </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"middle\"><paragraph>5% </paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>Wheezing </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"middle\"><paragraph>&lt;1% </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"middle\"><paragraph>1% </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"middle\"><paragraph>0 </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"middle\"><paragraph>2% </paragraph></td></tr><tr><td styleCode=\"Rrule Botrule Lrule \" valign=\"middle\"><paragraph>Edema Peripheral </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"middle\"><paragraph>&lt;1% </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"middle\"><paragraph>0 </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"middle\"><paragraph>1% </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"middle\"><paragraph>2% </paragraph></td></tr></tbody></table>","<table ID=\"_Reft4\" width=\"100%\"><caption>Table 4: Treatment-Emergent Adverse Events Occurring in &gt;1% of All Dexmedetomidine-Treated Adult Patients in the Randomized Placebo- Controlled Continuous Infusion &lt;24 Hours ICU Sedation Studies </caption><col width=\"33%\"/><col width=\"33%\"/><col width=\"33%\"/><tbody><tr><td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph> <content styleCode=\"bold\">Adverse Event</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Toprule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Randomized Dexmedetomidine</content> <content styleCode=\"bold\">(N = 387)</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Toprule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Placebo</content> <content styleCode=\"bold\">(N = 379)</content></paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>Hypotension </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"top\"><paragraph>28% </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"top\"><paragraph>13% </paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>Hypertension </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"top\"><paragraph>16% </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"top\"><paragraph>18% </paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>Nausea </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"top\"><paragraph>11% </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"top\"><paragraph>9% </paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>Bradycardia </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"top\"><paragraph>7% </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"top\"><paragraph>3% </paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>Fever </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"top\"><paragraph>5% </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"top\"><paragraph>4% </paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>Vomiting </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"top\"><paragraph>4% </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"top\"><paragraph>6% </paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>Atrial Fibrillation </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"top\"><paragraph>4% </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"top\"><paragraph>3% </paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>Hypoxia </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"top\"><paragraph>4% </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"top\"><paragraph>4% </paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>Tachycardia </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"top\"><paragraph>3% </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"top\"><paragraph>5% </paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>Hemorrhage </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"top\"><paragraph>3% </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"top\"><paragraph>4% </paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>Anemia </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"top\"><paragraph>3% </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"top\"><paragraph>2% </paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>Dry Mouth </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"top\"><paragraph>3% </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"top\"><paragraph>1% </paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>Rigors </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"top\"><paragraph>2% </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"top\"><paragraph>3% </paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>Agitation </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"top\"><paragraph>2% </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"top\"><paragraph>3% </paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>Hyperpyrexia </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"top\"><paragraph>2% </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"top\"><paragraph>3% </paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>Pain </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"top\"><paragraph>2% </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"top\"><paragraph>2% </paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>Hyperglycemia </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"top\"><paragraph>2% </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"top\"><paragraph>2% </paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>Acidosis </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"top\"><paragraph>2% </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"top\"><paragraph>2% </paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>Pleural Effusion </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"top\"><paragraph>2% </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"top\"><paragraph>1% </paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>Oliguria </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"top\"><paragraph>2% </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"top\"><paragraph>&lt;1% </paragraph></td></tr><tr><td styleCode=\"Rrule Botrule Lrule \" valign=\"top\"><paragraph>Thirst </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"top\"><paragraph>2% </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"top\"><paragraph>&lt;1% </paragraph></td></tr></tbody></table>","<table ID=\"_Reft5\" width=\"100%\"><caption>Table 5: Key Treatment-Emergent Adverse Events Occurring in Dexmedetomidine-or Midazolam-Treated Adult Patients in the Randomized Active Comparator Continuous Infusion Long-Term Intensive Care Unit Sedation Study </caption><col width=\"43%\"/><col width=\"29%\"/><col width=\"29%\"/><tfoot><tr><td align=\"left\" colspan=\"3\" valign=\"top\"><sup>&#x2020;</sup> Includes any type of hypertension. </td></tr><tr><td align=\"left\" colspan=\"3\" valign=\"top\"><sup>1</sup> Hypotension was defined in absolute terms as Systolic blood pressure of &lt;80 mmHg or Diastolic blood pressure of &lt;50 mmHg or in relative terms as &#x2264;30% lower than pre-study drug infusion value. </td></tr><tr><td align=\"left\" colspan=\"3\" valign=\"top\"><sup>2</sup> Bradycardia was defined in absolute terms as &lt;40 bpm or in relative terms as &#x2264;30% lower than pre-study drug infusion value. </td></tr><tr><td align=\"left\" colspan=\"3\" valign=\"top\"><sup>3</sup> Hypertension was defined in absolute terms as Systolic blood pressure &gt;180 mmHg or Diastolic blood pressure of &gt;100 mmHg or in relative terms as &#x2265;30% higher than pre-study drug infusion value. </td></tr><tr><td align=\"left\" colspan=\"3\" valign=\"top\"><sup>4</sup> Tachycardia was defined in absolute terms as &gt;120 bpm or in relative terms as &#x2265;30% greater than pre-study drug infusion value. </td></tr></tfoot><tbody><tr><td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"bottom\"><paragraph><content styleCode=\"bold\">Adverse Event</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Toprule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Dexmedetomidine (N = 244)</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Toprule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Midazolam (N = 122)</content></paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>Hypotension<sup>1</sup></paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"middle\"><paragraph>56% </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"middle\"><paragraph>56% </paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>Hypotension Requiring Intervention </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"middle\"><paragraph>28% </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"middle\"><paragraph>27% </paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>Bradycardia<sup>2</sup></paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"middle\"><paragraph>42% </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"middle\"><paragraph>19% </paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>Bradycardia Requiring Intervention </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"middle\"><paragraph>5% </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"middle\"><paragraph>1% </paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>Systolic Hypertension<sup>3</sup></paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"middle\"><paragraph>28% </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"middle\"><paragraph>42% </paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>Tachycardia<sup>4</sup></paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"middle\"><paragraph>25% </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"middle\"><paragraph>44% </paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>Tachycardia Requiring Intervention </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"middle\"><paragraph>10% </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"middle\"><paragraph>10% </paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>Diastolic Hypertension<sup>3</sup></paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"middle\"><paragraph>12% </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"middle\"><paragraph>15% </paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>Hypertension<sup>3</sup></paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"middle\"><paragraph>11% </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"middle\"><paragraph>15% </paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>Hypertension Requiring Intervention<sup>&#x2020;</sup></paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"middle\"><paragraph>19% </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"middle\"><paragraph>30% </paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>Hypokalemia </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"middle\"><paragraph>9% </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"middle\"><paragraph>13% </paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>Pyrexia </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"middle\"><paragraph>7% </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"middle\"><paragraph>2% </paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>Agitation </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"middle\"><paragraph>7% </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"middle\"><paragraph>6% </paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>Hyperglycemia </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"middle\"><paragraph>7% </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"middle\"><paragraph>2% </paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>Constipation </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"middle\"><paragraph>6% </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"middle\"><paragraph>6% </paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>Hypoglycemia </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"middle\"><paragraph>5% </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"middle\"><paragraph>6% </paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>Respiratory Failure </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"middle\"><paragraph>5% </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"middle\"><paragraph>3% </paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>Renal Failure Acute </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"middle\"><paragraph>2% </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"middle\"><paragraph>1% </paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>Acute Respiratory Distress Syndrome </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"middle\"><paragraph>2% </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"middle\"><paragraph>1% </paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>Generalized Edema </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"middle\"><paragraph>2% </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"middle\"><paragraph>6% </paragraph></td></tr><tr><td styleCode=\"Rrule Botrule Lrule \" valign=\"middle\"><paragraph>Hypomagnesemia </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"middle\"><paragraph>1% </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"middle\"><paragraph>7% </paragraph></td></tr></tbody></table>","<table ID=\"_Reft6\" width=\"100%\"><caption>Table 6: Number (%) of Adult Subjects Who Had a Dose-Related Increase in Treatment Emergent Adverse Events by Maintenance Adjusted Dose Rate Range in the Dexmedetomidine Hydrochloride Group </caption><col width=\"39%\"/><col width=\"22%\"/><col width=\"20%\"/><col width=\"18%\"/><tfoot><tr><td align=\"left\" colspan=\"4\" valign=\"top\"><sup>*</sup>Average maintenance dose over the entire study drug administration. </td></tr></tfoot><tbody><tr><td align=\"center\" colspan=\"4\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"bottom\"><paragraph><content styleCode=\"bold\">Dexmedetomidine Hydrochloride (mcg/kg/hr)</content></paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"bottom\"><paragraph><content styleCode=\"bold\">Adverse Event</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">&#x2264;0.7*</content> <content styleCode=\"bold\">(N = 95)</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">&gt;0.7 to &#x2264;1.1*</content> <content styleCode=\"bold\">(N = 78)</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">&gt;1.1*</content> <content styleCode=\"bold\">(N = 71)</content></paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>Constipation </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"middle\"><paragraph>6% </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"middle\"><paragraph>5% </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"middle\"><paragraph>14% </paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>Agitation </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"middle\"><paragraph>5% </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"middle\"><paragraph>8% </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"middle\"><paragraph>14% </paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>Anxiety </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"middle\"><paragraph>5% </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"middle\"><paragraph>5% </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"middle\"><paragraph>9% </paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>Edema Peripheral </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"middle\"><paragraph>3% </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"middle\"><paragraph>5% </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"middle\"><paragraph>7% </paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>Atrial Fibrillation </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"middle\"><paragraph>2% </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"middle\"><paragraph>4% </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"middle\"><paragraph>9% </paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>Respiratory Failure </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"middle\"><paragraph>2% </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"middle\"><paragraph>6% </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"middle\"><paragraph>10% </paragraph></td></tr><tr><td styleCode=\"Rrule Botrule Lrule \" valign=\"middle\"><paragraph>Acute Respiratory Distress Syndrome </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"middle\"><paragraph>1% </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"middle\"><paragraph>3% </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"middle\"><paragraph>9% </paragraph></td></tr></tbody></table>","<table ID=\"_Reft7\" width=\"100%\"><caption>Table 7: Adverse Reactions with an Incidence &gt;2%-Adult Procedural Sedation Population </caption><col width=\"38%\"/><col width=\"29%\"/><col width=\"34%\"/><tfoot><tr><td align=\"left\" colspan=\"3\" valign=\"top\"><sup>1</sup> Hypotension was defined in absolute and relative terms as Systolic blood pressure of &lt;80 mmHg or &#x2264;30% lower than pre-study drug infusion value, or Diastolic blood pressure of &lt;50 mmHg. </td></tr><tr><td align=\"left\" colspan=\"3\" valign=\"top\"><sup>2</sup> Respiratory depression was defined in absolute and relative terms as respiratory rate (RR) &lt;8 beats per minute or &gt;25% decrease from baseline. </td></tr><tr><td align=\"left\" colspan=\"3\" valign=\"top\"><sup>3</sup> Bradycardia was defined in absolute and relative terms as &lt;40 beats per minute or &#x2264;30% lower than pre-study drug infusion value. Subjects in Study 2 were pretreated with glycopyrrolate 0.1 mg intravenously before receiving study drug <content styleCode=\"italics\">[see Clinical Studies (<linkHtml href=\"#s73\">14.2</linkHtml>)].</content></td></tr><tr><td align=\"left\" colspan=\"3\" valign=\"top\"><sup>4</sup> Hypertension was defined in absolute and relative terms as Systolic blood pressure &gt;180 mmHg or &#x2265;30% higher than pre-study drug infusion value or Diastolic blood pressure of &gt;100 mmHg. </td></tr><tr><td align=\"left\" colspan=\"3\" valign=\"top\"><sup>5</sup> Tachycardia was defined in absolute and relative terms as &gt;120 beats per minute or &#x2265;30% greater than pre-study drug infusion value. </td></tr><tr><td align=\"left\" colspan=\"3\" valign=\"top\"><sup>6</sup> Hypoxia was defined in absolute and relative terms as S<sub>p</sub>O<sub>2</sub> &lt;90% or 10% decrease from baseline. </td></tr></tfoot><tbody><tr><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"middle\"><paragraph><content styleCode=\"bold\">Adverse Event</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Toprule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Dexmedetomidine Hydrochloride</content> <content styleCode=\"bold\">(N = 318)</content> <content styleCode=\"bold\">(%)</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Toprule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Placebo</content> <content styleCode=\"bold\">(N = 113)</content> <content styleCode=\"bold\">(%)</content></paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>Hypotension<sup>1</sup></paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"middle\"><paragraph>54% </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"middle\"><paragraph>30% </paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>Respiratory Depression<sup>2</sup></paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"middle\"><paragraph>37% </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"middle\"><paragraph>32% </paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>Bradycardia<sup>3</sup></paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"middle\"><paragraph>14% </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"middle\"><paragraph>4% </paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>Hypertension<sup>4</sup></paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"middle\"><paragraph>13% </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"middle\"><paragraph>24% </paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>Tachycardia<sup>5</sup></paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"middle\"><paragraph>5% </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"middle\"><paragraph>17% </paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>Nausea </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"middle\"><paragraph>3% </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"middle\"><paragraph>2% </paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>Dry Mouth </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"middle\"><paragraph>3% </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"middle\"><paragraph>1% </paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>Hypoxia<sup>6</sup></paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"middle\"><paragraph>2% </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"middle\"><paragraph>3% </paragraph></td></tr><tr><td styleCode=\"Rrule Botrule Lrule \" valign=\"middle\"><paragraph>Bradypnea </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"middle\"><paragraph>2% </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"middle\"><paragraph>4% </paragraph></td></tr></tbody></table>","<table ID=\"_Reft9\" width=\"100%\"><caption>Table 9: Adverse Reactions Experienced During Post-Approval Use of Dexmedetomidine Hydrochloride </caption><col width=\"38%\"/><col width=\"62%\"/><tbody><tr><td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"middle\"><paragraph><content styleCode=\"bold\">System Organ Class</content></paragraph></td><td styleCode=\"Rrule Botrule Toprule \" valign=\"middle\"><paragraph><content styleCode=\"bold\">Preferred Term</content></paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>Blood and Lymphatic System Disorders </paragraph></td><td styleCode=\"Rrule Botrule \" valign=\"top\"><paragraph>Anemia </paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>Cardiac Disorders </paragraph></td><td styleCode=\"Rrule Botrule \" valign=\"top\"><paragraph>Arrhythmia, atrial fibrillation, atrioventricular block, bradycardia, cardiac arrest, cardiac disorder, extrasystoles, myocardial infarction, supraventricular tachycardia, tachycardia, ventricular arrhythmia, ventricular tachycardia </paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>Eye Disorders </paragraph></td><td styleCode=\"Rrule Botrule \" valign=\"middle\"><paragraph>Photopsia, visual impairment </paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>Gastrointestinal Disorders </paragraph></td><td styleCode=\"Rrule Botrule \" valign=\"middle\"><paragraph>Abdominal pain, diarrhea, nausea, vomiting </paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>General Disorders and Administration Site Conditions </paragraph></td><td styleCode=\"Rrule Botrule \" valign=\"top\"><paragraph>Chills, hyperpyrexia, pain, pyrexia, thirst </paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>Hepatobiliary Disorders </paragraph></td><td styleCode=\"Rrule Botrule \" valign=\"middle\"><paragraph>Hepatic function abnormal, hyperbilirubinemia </paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>Investigations </paragraph></td><td styleCode=\"Rrule Botrule \" valign=\"top\"><paragraph>Alanine aminotransferase increased, aspartate aminotransferase increased, blood alkaline phosphatase increased, blood urea increased, electrocardiogram T wave inversion, gammaglutamyltransferase increased, electrocardiogram QT prolonged </paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>Metabolism and Nutrition Disorders </paragraph></td><td styleCode=\"Rrule Botrule \" valign=\"top\"><paragraph>Acidosis, hyperkalemia, hypoglycemia, hypovolemia, hypernatremia </paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>Nervous System Disorders </paragraph></td><td styleCode=\"Rrule Botrule \" valign=\"top\"><paragraph>Convulsion, dizziness, headache, neuralgia, neuritis, speech disorder </paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>Psychiatric Disorders </paragraph></td><td styleCode=\"Rrule Botrule \" valign=\"middle\"><paragraph>Agitation, confusional state, delirium, hallucination, illusion </paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>Renal and Urinary Disorders </paragraph></td><td styleCode=\"Rrule Botrule \" valign=\"middle\"><paragraph>Oliguria, polyuria </paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>Respiratory, Thoracic and Mediastinal Disorders </paragraph></td><td styleCode=\"Rrule Botrule \" valign=\"top\"><paragraph>Apnea, bronchospasm, dyspnea, hypercapnia, hypoventilation, hypoxia, pulmonary congestion, respiratory acidosis </paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>Skin and Subcutaneous Tissue Disorders </paragraph></td><td styleCode=\"Rrule Botrule \" valign=\"top\"><paragraph>Hyperhidrosis, pruritus, rash, urticaria </paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>Surgical and Medical Procedures </paragraph></td><td styleCode=\"Rrule Botrule \" valign=\"middle\"><paragraph>Light anesthesia </paragraph></td></tr><tr><td styleCode=\"Rrule Botrule Lrule \" valign=\"middle\"><paragraph>Vascular Disorders </paragraph></td><td styleCode=\"Rrule Botrule \" valign=\"middle\"><paragraph>Blood pressure fluctuation, hemorrhage, hypertension, hypotension </paragraph></td></tr></tbody></table>"],"information_for_patients":["17 PATIENT COUNSELING INFORMATION Dexmedetomidine Injection is indicated for short-term intravenous sedation. Dosage must be individualized and titrated to the desired clinical effect. Blood pressure, heart rate and oxygen levels will be monitored both continuously during the infusion of Dexmedetomidine Injection and as clinically appropriate after discontinuation. • When Dexmedetomidine Injection is infused for more than 6 hours, patients should be informed to report nervousness, agitation, and headaches that may occur for up to 48 hours. • Additionally, patients should be informed to report symptoms that may occur within 48 hours after the administration of Dexmedetomidine Injection such as: weakness, confusion, excessive sweating, weight loss, abdominal pain, salt cravings, diarrhea, constipation, dizziness or light-headedness. • Advise breastfeeding mothers who were exposed to Dexmedetomidine Injection to monitor breastfed neonates for irritability [see Use in Specific Populations ( 8.2 )] . www.fresenius-kabi.com/us 451212F dexme-img-01.jpg"],"dosage_and_administration":["2 DOSAGE AND ADMINISTRATION • Individualize and titrate dexmedetomidine injection dosing to desired clinical effect. ( 2.1 ) • Administer dexmedetomidine injection using a controlled infusion device. ( 2.1 ) • Dilute the 200 mcg/ 2mL (100 mcg/mL) vial contents in 0.9% sodium chloride solution to achieve required concentration (4 mcg/mL) prior to administration. ( 2.4 ) • For Adult Intensive Care Unit Sedation : Initiate at one mcg/kg over 10 minutes , followed by a maintenance infusion of 0.2 to 0.7 mcg/kg/ hour . ( 2.2 ) • For Adult Procedural Sedation : Initiate at one mcg/kg over 10 minutes , followed by a maintenance infusion initiated at 0.6 mcg/kg/ hour and titrated to achieve desired clinical effect with doses ranging from 0.2 to 1 mcg/kg/ hour . ( 2.2 ) • Alternative Doses : Recommended for patients over 65 years of age and awake fiberoptic intubation patients. ( 2.2 ) 2.1 Administration Instructions • Dexmedetomidine Injection dosing should be individualized and titrated to desired clinical response. • Dexmedetomidine Injection is not indicated for infusions lasting longer than 24 hours. • Dexmedetomidine Injection should be administered using a controlled infusion device. 2.2 Recommended Dosage Table 1: Recommended Dosage in Adult Patients INDICATION DOSAGE AND ADMINISTRATION Initiation of Intensive Care Unit Sedation For adult patients : a loading infusion of one mcg/kg over 10 minutes . For adult patients being converted from alternate sedative therapy : a loading dose may not be required. For patients over 65 years of age : Consider a dose reduction [see Use in Specific Populations ( 8.5 )] . For adult patients with impaired hepatic function : Consider a dose reduction [see Use in Specific Populations ( 8.6 ), Clinical Pharmacology ( 12.3 )] . Maintenance of Intensive Care Unit Sedation For adult patients : a maintenance infusion of 0.2 to 0.7 mcg/kg/ hour . The rate of the maintenance infusion should be adjusted to achieve the desired level of sedation. For patients over 65 years of age : Consider a dose reduction [see Use in Specific Populations ( 8.5 )]. For adult patients with impaired hepatic function : Consider a dose reduction [see Use in Specific Populations ( 8.6 ), Clinical Pharmacology ( 12.3 )] Initiation of Procedural Sedation For adult patients : a loading infusion of one mcg/kg over 10 minutes . For less invasive procedures such as ophthalmic surgery, a loading infusion of 0.5 mcg/kg given over 10 minutes may be suitable. For awake fiberoptic intubation in adult patients : a loading infusion of one mcg/kg over 10 minutes . For patients over 65 years of age : a loading infusion of 0.5 mcg/kg over 10 minutes [see Use in Specific Populations ( 8.5 )]. For adult patients with impaired hepatic function : Consider a dose reduction [see Use in Specific Populations ( 8.6 ), Clinical Pharmacology ( 12.3 )]. Maintenance of Procedural Sedation For adult patients : the maintenance infusion is generally initiated at 0.6 mcg/kg/ hour and titrated to achieve desired clinical effect with doses ranging from 0.2 to 1 mcg/kg/ hour . Adjust the rate of the maintenance infusion to achieve the targeted level of sedation. For awake fiberoptic intubation in adult patients : a maintenance infusion of 0.7 mcg/kg/ hour is recommended until the endotracheal tube is secured. For patients over 65 years of age : Consider a dose reduction [see Use in Specific Populations ( 8.5 )] . For adult patients with impaired hepatic function : Consider a dose reduction [see Use in Specific Populations ( 8.6 ), Clinical Pharmacology ( 12.3 )] . Pediatric use information is approved for Hospira Inc.'s PRECEDEX TM (dexmedetomidine hydrochloride) injection. However, due to Hospira Inc.'s marketing exclusivity rights, this drug product is not labeled with that information. 2.3 Dosage Adjustment Due to possible pharmacodynamic interactions, a reduction in dosage of Dexmedetomidine Injection or other concomitant anesthetics, sedatives, hypnotics or opioids may be required when co-administered [see Drug Interactions ( 7.1 )] . Dosage reductions may need to be considered for adult patients with hepatic impairment, and geriatric patients [see Warnings and Precautions ( 5.8 ), Use in Specific Populations ( 8.6 ), Clinical Pharmacology ( 12.3 )] . 2.4 Preparation of Solution Strict aseptic technique must always be maintained during handling of Dexmedetomidine Injection. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. Do not use if product is discolored or if precipitate matter is present. Dexmedetomidine Injection, 200 mcg/2 mL (100 mcg/mL) Dexmedetomidine Injection must be diluted with 0.9% sodium chloride injection to achieve required concentration (4 mcg/mL) prior to administration. Preparation of solutions is the same, whether for the loading dose or maintenance infusion. To prepare the infusion, withdraw 2 mL of Dexmedetomidine Injection, and add to 48 mL of 0.9% sodium chloride injection to a total of 50 mL. Shake gently to mix well. 2.5 Administration with Other Fluids Dexmedetomidine Injection infusion should not be co-administered through the same intravenous catheter with blood or plasma because physical compatibility has not been established. Dexmedetomidine Injection has been shown to be incompatible when administered with the following drugs: amphotericin B, diazepam. Dexmedetomidine Injection has been shown to be compatible when administered with the following intravenous fluids: • 0.9% sodium chloride in water • 5% dextrose in water • 20% mannitol • Lactated Ringer's solution • 100 mg/mL magnesium sulfate solution • 0.3% potassium chloride solution 2.6 Compatibility with Natural Rubber Compatibility studies have demonstrated the potential for absorption of Dexmedetomidine Injection to some types of natural rubber. Although Dexmedetomidine Injection is dosed to effect, it is advisable to use administration components made with synthetic or coated natural rubber gaskets."],"drug_abuse_and_dependence":["9 DRUG ABUSE AND DEPENDENCE 9.1 Controlled Substance Dexmedetomidine Hydrochloride is not a controlled substance. 9.3 Dependence The dependence potential of Dexmedetomidine Injection has not been studied in humans. However, since studies in rodents and primates have demonstrated that Dexmedetomidine Injection exhibits pharmacologic actions similar to those of clonidine, it is possible that Dexmedetomidine Injection may produce a clonidine-like withdrawal syndrome upon abrupt discontinuation [see Warnings and Precautions ( 5.5 )] ."],"spl_product_data_elements":["Dexmedetomidine Hydrochloride dexmedetomidine hydrochloride DEXMEDETOMIDINE HYDROCHLORIDE DEXMEDETOMIDINE SODIUM CHLORIDE SODIUM ACETATE ACETIC ACID"],"dosage_forms_and_strengths":["3 DOSAGE FORMS AND STRENGTHS Dexmedetomidine Injection, USP is clear and colorless and is available as follows. Dexmedetomidine Injection, USP, 200 mcg (dexmedetomidine)/2 mL [100 mcg (dexmedetomidine)/mL] in a single-dose glass vial. To be used after dilution. Dexmedetomidine Injection, USP, 200 mcg (dexmedetomidine)/2 mL [100 mcg (dexmedetomidine)/mL] in a single-dose glass vial. To be used after dilution. ( 3 )"],"recent_major_changes_table":["<table styleCode=\"Noautorules\" width=\"100%\"><col width=\"81%\"/><col width=\"19%\"/><tbody><tr><td valign=\"top\"><paragraph>Dosage and Administration, Preparation of Solution (<linkHtml href=\"#s9\">2.4</linkHtml>) </paragraph></td><td align=\"right\" valign=\"top\"><paragraph>08/2022 </paragraph></td></tr><tr><td valign=\"top\"><paragraph>Warnings and Precautions, Hyperthermia or Pyrexia (<linkHtml href=\"#s23\">5.7</linkHtml>) </paragraph></td><td align=\"right\" valign=\"top\"><paragraph>08/2022 </paragraph></td></tr></tbody></table>"],"clinical_pharmacology_table":["<table ID=\"_Reft10\" width=\"100%\"><caption>Table 10: Mean &#xB1; SD Pharmacokinetic Parameters in Adults </caption><col width=\"17%\"/><col width=\"21%\"/><col width=\"21%\"/><col width=\"21%\"/><col width=\"21%\"/><tfoot><tr><td align=\"left\" colspan=\"5\" valign=\"top\">Abbreviations: t<sub>1/2</sub> = half-life, CL = clearance, V<sub>ss</sub> = steady-state volume of distribution. </td></tr><tr><td align=\"left\" colspan=\"5\" valign=\"top\">* Presented as harmonic mean and pseudo standard deviation. </td></tr><tr><td align=\"left\" colspan=\"5\" valign=\"top\"><sup>#</sup> Mean C<sub>ss</sub> = Average steady-state concentration of Dexmedetomidine Injection. The mean C<sub>ss</sub> was calculated based on post-dose sampling from 2.5 to 9 hours samples for 12 hour infusion and post-dose sampling from 2.5 to 18 hours for 24 hour infusions. </td></tr></tfoot><tbody><tr><td rowspan=\"4\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"bottom\"><paragraph><content styleCode=\"bold\">Parameter</content> </paragraph></td><td align=\"center\" colspan=\"4\" styleCode=\"Rrule Botrule Toprule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Loading Infusion (min)/Total Infusion Duration (hrs)</content> </paragraph></td></tr><tr><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">10 min/12 hrs</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">10 min/24 hrs</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">10 min/24 hrs</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">35 min/24 hrs</content></paragraph></td></tr><tr><td align=\"center\" colspan=\"4\" styleCode=\"Rrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Dexmedetomidine Target Plasma Concentration (ng/mL) and Dose (mcg/kg/hr)</content></paragraph></td></tr><tr><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">0.3/0.17</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">0.3/0.17</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">0.6/0.33</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">1.25/0.70</content></paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">t<sub>1/2</sub>*, hour</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"top\"><paragraph>1.78 &#xB1; 0.30 </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"top\"><paragraph>2.22 &#xB1; 0.59 </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"top\"><paragraph>2.23 &#xB1; 0.21 </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"top\"><paragraph>2.50 &#xB1; 0.61 </paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">CL, liter/hour</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"top\"><paragraph>46.3 &#xB1; 8.3 </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"top\"><paragraph>43.1 &#xB1; 6.5 </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"top\"><paragraph>35.3 &#xB1; 6.8 </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"top\"><paragraph>36.5 &#xB1; 7.5 </paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">V<sub>ss</sub>, liter</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"top\"><paragraph>88.7 &#xB1; 22.9 </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"top\"><paragraph>102.4 &#xB1; 20.3 </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"top\"><paragraph>93.6 &#xB1; 17.0 </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"top\"><paragraph>99.6 &#xB1; 17.8 </paragraph></td></tr><tr><td align=\"center\" styleCode=\"Rrule Botrule Lrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Avg C<sub>ss </sub><sup>#</sup>, ng/mL</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"top\"><paragraph>0.27 &#xB1; 0.05 </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"top\"><paragraph>0.27 &#xB1; 0.05 </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"top\"><paragraph>0.67 &#xB1; 0.10 </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"top\"><paragraph>1.37 &#xB1; 0.20 </paragraph></td></tr></tbody></table>"],"use_in_specific_populations":["8 USE IN SPECIFIC POPULATIONS • Geriatric Patients: Dose reduction should be considered. ( 2.2 , 2.3 , 5.2 , 8.5 ) • Hepatic Impairment: Dose reduction should be considered. ( 2.2 , 2.3 , 5.8 , 8.6 ) Pediatric use information is approved for Hospira Inc.'s PRECEDEX TM (dexmedetomidine hydrochloride) injection. However, due to Hospira Inc.'s marketing exclusivity rights, this drug product is not labeled with that information. 8.1 Pregnancy Risk Summary Available data from published randomized controlled trials and case reports over several decades of use with intravenously administered dexmedetomidine during pregnancy have not identified a drug-associated risk of major birth defects and miscarriage; however, the reported exposures occurred after the first trimester. Most of the available data are based on studies with exposures that occurred at the time of caesarean section delivery, and these studies have not identified an adverse effect on maternal outcomes or infant Apgar scores. Available data indicate that dexmedetomidine crosses the placenta. In animal reproduction studies, fetal toxicity that lower fetal viability and reduced live fetuses occurred with subcutaneous administration of dexmedetomidine to pregnant rats during organogenesis at doses 1.8 times the maximum recommended human dose (MRHD) of 17.8 mcg/kg/day. Developmental toxicity (low pup weights and adult offspring weights, decreased F1 grip strength, increased early implantation loss and decreased viability of second-generation offspring) occurred when pregnant rats were subcutaneously administered dexmedetomidine at doses less than the clinical dose from late pregnancy through lactation and weaning (see Data ) . The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively. Data Animal Data Increased post-implantation losses and reduced live fetuses in the presence of maternal toxicity (i.e. decreased body weight) were noted in a rat embryo-fetal development study in which pregnant dams were administered subcutaneous doses of dexmedetomidine 200 mcg/kg/day (equivalent to 1.8 times the intravenous MRHD of 17.8 mcg/kg/day based on body surface area [BSA]) during the period of organogenesis (Gestation Day [GD] 6 to 15). No malformations were reported. No malformations or embryo-fetal toxicity were noted in a rabbit embryo-fetal development study in which pregnant does were administered dexmedetomidine intravenously at doses of up to 96 mcg/kg/day (approximately half the human exposure at the MRHD based on AUC) during the period of organogenesis (GD 6 to 18). Reduced pup and adult offspring birth weights, and grip strength were reported in a rat developmental toxicology study in which pregnant females were administered dexmedetomidine subcutaneously at doses of 8 mcg/kg/day (0.07 times the MRHD based on BSA) during late pregnancy through lactation and weaning (GD 16 to postnatal day [PND] 25). Decreased viability of second generation offspring and an increase in early implantation loss along with delayed motor development occurred in the 32 mcg/kg/day group (equivalent to less than the clinical dose based on BSA) when first generation offspring were allowed to mate. This study limited dosing to hard palate closure (GD 15 to 18) through weaning instead of dosing from implantation (GD 6 to 7) to weaning (PND 21). In a study in the pregnant rat, placental transfer of dexmedetomidine was observed when radiolabeled dexmedetomidine was administered subcutaneously. 8.2 Lactation Risk Summary Available published literature reports the presence of dexmedetomidine in human milk following intravenous administration (see Data ) . There is no information regarding the effects of dexmedetomidine on the breastfed infant or the effects on milk production. Advise women to monitor the breastfed infant for irritability. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for Dexmedetomidine Injection and any potential adverse effects on the breastfed infant from Dexmedetomidine Injection or from the underlying condition. Data In two published clinical studies, a total of 14 women were given intravenous dexmedetomidine 6 mcg/kg/hour for 10 minutes after delivery followed by continuous infusion of 0.2–0.7 mcg/kg/hour. Breast milk and maternal blood samples were collected at 0, 6, 12, and 24 hours after discontinuation of dexmedetomidine. Plasma and milk dexmedetomidine concentrations were detectable up to 6 hours in most subjects, up to 12 hours in one subject and undetectable in all at 24 hours. The milk-to-plasma ratio from single paired maternal milk and plasma concentrations at each time point ranged from 0.53 to 0.95. The relative infant dose was estimated to range from 0.02 to 0.098%. 8.4 Pediatric Use Sedation for Non-Invasive Procedures The safety and effectiveness of Dexmedetomidine Injection have not been established in pediatric patients less than 1 month of age. Pediatric use information is approved for Hospira Inc.'s PRECEDEX TM (dexmedetomidine hydrochloride) injection. However, due to Hospira Inc.'s marketing exclusivity rights, this drug product is not labeled with that information. ICU Sedation The safety and efficacy of Dexmedetomidine Injection have not been established in pediatric patients for ICU sedation. One assessor-blinded trial in pediatric patients and two open label studies in neonates were conducted to assess efficacy for ICU sedation. These studies did not meet their primary efficacy endpoints and the safety data submitted were insufficient to fully characterize the safety profile of Dexmedetomidine Injection for these patient populations. 8.5 Geriatric Use Intensive Care Unit Sedation A total of 729 patients in the clinical studies were 65 years of age and over. A total of 200 patients were 75 years of age and over. In patients greater than 65 years of age, a higher incidence of bradycardia and hypotension was observed following administration of Dexmedetomidine Hydrochloride [see Warnings and Precautions ( 5.2 )] . Therefore, a dose reduction may be considered in patients over 65 years of age [see Dosage and Administration ( 2.2 , 2.3 ), Clinical Pharmacology ( 12.3 )] . Procedural Sedation A total of 131 patients in the clinical studies were 65 years of age and over. A total of 47 patients were 75 years of age and over. Hypotension occurred in a higher incidence in Dexmedetomidine Injection-treated patients 65 years or older (72%) and 75 years or older (74%) as compared to patients <65 years (47%). A reduced loading dose of 0.5 mcg/kg given over 10 minutes is recommended and a reduction in the maintenance infusion should be considered for patients greater than 65 years of age. 8.6 Hepatic Impairment Since Dexmedetomidine Injection clearance decreases with increasing severity of hepatic impairment, dose reduction should be considered in patients with impaired hepatic function [see Dosage and Administration ( 2.2 , 2.3 ), Clinical Pharmacology ( 12.3 )] ."],"dosage_and_administration_table":["<table width=\"100%\"><caption>Table 1: Recommended Dosage in Adult Patients </caption><col width=\"27%\"/><col width=\"73%\"/><tbody><tr><td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"middle\"><paragraph><content styleCode=\"bold\">INDICATION</content></paragraph></td><td styleCode=\"Rrule Botrule Toprule \" valign=\"middle\"><paragraph><content styleCode=\"bold\">DOSAGE AND ADMINISTRATION</content></paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Initiation of Intensive Care Unit Sedation</content></paragraph></td><td styleCode=\"Rrule Botrule \" valign=\"bottom\"><paragraph><content styleCode=\"underline\">For adult patients</content>: a loading infusion of one mcg/kg over 10 <content styleCode=\"italics\"><content styleCode=\"underline\">minutes</content></content>.  <content styleCode=\"underline\">For adult patients being converted from alternate sedative therapy</content>: a loading dose may not be required.  <content styleCode=\"underline\">For patients over 65 years of age</content>: Consider a dose reduction <content styleCode=\"italics\">[see Use in Specific Populations (<linkHtml href=\"#s42\">8.5</linkHtml>)]</content>.  <content styleCode=\"underline\">For adult patients with impaired hepatic function</content>: Consider a dose reduction <content styleCode=\"italics\">[see Use in Specific Populations (<linkHtml href=\"#s45\">8.6</linkHtml>), Clinical Pharmacology (<linkHtml href=\"#s54\">12.3</linkHtml>)]</content>. </paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Maintenance of Intensive Care Unit Sedation</content></paragraph></td><td styleCode=\"Rrule Botrule \" valign=\"bottom\"><paragraph><content styleCode=\"underline\">For adult patients</content>: a maintenance infusion of 0.2 to 0.7 mcg/kg/<content styleCode=\"italics\"><content styleCode=\"underline\">hour</content></content>. The rate of the maintenance infusion should be adjusted to achieve the desired level of sedation.  <content styleCode=\"underline\">For patients over 65 years of age</content>: Consider a dose reduction <content styleCode=\"italics\">[see Use in Specific Populations (<linkHtml href=\"#s42\">8.5</linkHtml>)].</content>  <content styleCode=\"underline\">For adult patients with impaired hepatic function</content>: Consider a dose reduction <content styleCode=\"italics\">[see Use in Specific Populations (<linkHtml href=\"#s45\">8.6</linkHtml>), Clinical Pharmacology (<linkHtml href=\"#s54\">12.3</linkHtml>)]</content></paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Initiation of Procedural Sedation</content></paragraph></td><td styleCode=\"Rrule Botrule \" valign=\"bottom\"><paragraph><content styleCode=\"underline\">For adult patients</content>: a loading infusion of one mcg/kg over 10 <content styleCode=\"italics\"><content styleCode=\"underline\">minutes</content></content>. For less invasive procedures such as ophthalmic surgery, a loading infusion of 0.5 mcg/kg given over 10 <content styleCode=\"italics\"><content styleCode=\"underline\">minutes</content></content> may be suitable.  <content styleCode=\"underline\">For awake fiberoptic intubation in adult patients</content>: a loading infusion of one mcg/kg over 10 <content styleCode=\"italics\"><content styleCode=\"underline\">minutes</content></content>.  <content styleCode=\"underline\">For patients over 65 years of age</content>: a loading infusion of 0.5 mcg/kg over 10 <content styleCode=\"italics\"><content styleCode=\"underline\">minutes</content> [see Use in Specific Populations (<linkHtml href=\"#s42\">8.5</linkHtml>)].</content>  <content styleCode=\"underline\">For adult patients with impaired hepatic function</content>: Consider a dose reduction <content styleCode=\"italics\">[see Use in Specific Populations (<linkHtml href=\"#s45\">8.6</linkHtml>), Clinical Pharmacology (<linkHtml href=\"#s54\">12.3</linkHtml>)].</content></paragraph></td></tr><tr><td styleCode=\"Rrule Botrule Lrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Maintenance of Procedural Sedation</content></paragraph></td><td styleCode=\"Rrule Botrule \" valign=\"bottom\"><paragraph><content styleCode=\"underline\">For adult patients</content>: the maintenance infusion is generally initiated at 0.6 mcg/kg/<content styleCode=\"italics\"><content styleCode=\"underline\">hour</content></content> and titrated to achieve desired clinical effect with doses ranging from 0.2 to 1 mcg/kg/<content styleCode=\"italics\"><content styleCode=\"underline\">hour</content></content>. Adjust the rate of the maintenance infusion to achieve the targeted level of sedation.  <content styleCode=\"underline\">For awake fiberoptic intubation in adult patients</content>: a maintenance infusion of 0.7 mcg/kg/<content styleCode=\"italics\"><content styleCode=\"underline\">hour</content></content> is recommended until the endotracheal tube is secured.  <content styleCode=\"underline\">For patients over 65 years of age</content>: Consider a dose reduction <content styleCode=\"italics\">[see Use in Specific Populations (<linkHtml href=\"#s42\">8.5</linkHtml>)]</content>.  <content styleCode=\"underline\">For adult patients with impaired hepatic function</content>: Consider a dose reduction <content styleCode=\"italics\">[see Use in Specific Populations (<linkHtml href=\"#s45\">8.6</linkHtml>), Clinical Pharmacology (<linkHtml href=\"#s54\">12.3</linkHtml>)]</content>. </paragraph></td></tr></tbody></table>"],"animal_pharmacology_and_or_toxicology":["13.2 Animal Toxicology and/or Pharmacology There were no differences in the adrenocorticotropic hormone (ACTH)-stimulated cortisol response in dogs following a single dose of dexmedetomidine compared to saline control. However, after continuous subcutaneous infusions of dexmedetomidine at 3 mcg/kg/hr and 10 mcg/kg/hr for one week in dogs (exposures estimated to be within the clinical range), the ACTH-stimulated cortisol response was diminished by approximately 27% and 40%, respectively, compared to saline-treated control animals indicating a dose-dependent adrenal suppression."],"package_label_principal_display_panel":["PACKAGE LABEL - PRINCIPAL DISPLAY - Dexmedetomidine Hydrochloride 2 mL Vial Label NDC 65219-642-01 RF462102 Dexmedetomidine Injection, USP 200 mcg (base) per 2 mL (100 mcg (base) per mL) For intravenous infusion. MUST BE DILUTED . Discard unused portion. 2 mL Single-Dose Vial Rx only dexme-label-01.jpg","PACKAGE LABEL - PRINCIPAL DISPLAY - Dexmedetomidine Hydrochloride 2 mL Vial Tray Label NDC 65219-642-02 RF462102 Dexmedetomidine Injection, USP 200 mcg* per 2 mL (100 mcg per mL) For intravenous infusion. MUST BE DILUTED . Discard unused portion. Preservative free. 25 x 2 mL Single-Dose Vials Rx only dexme-label-02.jpg"],"carcinogenesis_and_mutagenesis_and_impairment_of_fertility":["13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility Carcinogenesis Animal carcinogenicity studies have not been performed with dexmedetomidine. Mutagenesis Dexmedetomidine was not mutagenic in vitro , in either the bacterial reverse mutation assay ( E. coli and Salmonella typhimurium ) or the mammalian cell forward mutation assay (mouse lymphoma). Dexmedetomidine was clastogenic in the in vitro human lymphocyte chromosome aberration test with, but not without, rat S9 metabolic activation. In contrast, dexmedetomidine was not clastogenic in the in vitro human lymphocyte chromosome aberration test with or without human S9 metabolic activation. Although dexmedetomidine was clastogenic in an in vivo mouse micronucleus test in NMRI mice, there was no evidence of clastogenicity in CD-1 mice. Impairment of Fertility Fertility in male or female rats was not affected after daily subcutaneous injections of dexmedetomidine at doses up to 54 mcg/kg (less than the maximum recommended human intravenous dose on a mcg/m 2 basis) administered from 10 weeks prior to mating in males, and 3 weeks prior to mating and during mating in females."]},"tags":[],"safety":{"boxedWarnings":[],"safetySignals":[{"date":"","signal":"BRADYCARDIA","source":"FDA FAERS","actionTaken":"243 reports"},{"date":"","signal":"OFF LABEL USE","source":"FDA FAERS","actionTaken":"227 reports"},{"date":"","signal":"HYPOTENSION","source":"FDA FAERS","actionTaken":"168 reports"},{"date":"","signal":"CARDIAC ARREST","source":"FDA FAERS","actionTaken":"166 reports"},{"date":"","signal":"PYREXIA","source":"FDA FAERS","actionTaken":"107 reports"},{"date":"","signal":"DRUG INEFFECTIVE","source":"FDA FAERS","actionTaken":"94 reports"},{"date":"","signal":"PNEUMONIA","source":"FDA FAERS","actionTaken":"93 reports"},{"date":"","signal":"PRODUCT USE IN UNAPPROVED INDICATION","source":"FDA FAERS","actionTaken":"89 reports"},{"date":"","signal":"PRODUCT USE ISSUE","source":"FDA FAERS","actionTaken":"87 reports"},{"date":"","signal":"DRUG INTERACTION","source":"FDA FAERS","actionTaken":"84 reports"}],"drugInteractions":[{"drug":"Anesthetics, Sedatives, Hypnotics, Opioids","action":"Adjust dose","effect":"Enhancement of pharmacodynamic effects"},{"drug":"Anesthetics, Sedatives, Hypnotics, Opioids","action":"Adjust dose","effect":"Enhancement of effects"},{"drug":"Isoflurane","action":"Adjust dose","effect":"Pharmacodynamic interactions"},{"drug":"Propofol","action":"Adjust dose","effect":"Pharmacodynamic interactions"},{"drug":"Alfentanil","action":"Adjust dose","effect":"Pharmacodynamic interactions"},{"drug":"Midazolam","action":"Adjust dose","effect":"Pharmacodynamic interactions"},{"drug":"Rocuronium","action":"No action required","effect":"No clinically meaningful increases in the magnitude of neuromuscular blockade"}],"commonSideEffects":[{"effect":"Hypotension","drugRate":"25%","severity":"mild","_validated":true},{"effect":"Hypertension","drugRate":"12%","severity":"mild","_validated":true},{"effect":"Nausea","drugRate":"9%","severity":"mild","_validated":true},{"effect":"Bradycardia","drugRate":"5%","severity":"mild","_validated":true},{"effect":"Atrial Fibrillation","drugRate":"4%","severity":"mild","_validated":true},{"effect":"Pyrexia","drugRate":"4%","severity":"mild","_validated":true},{"effect":"Dry Mouth","drugRate":"4%","severity":"mild","_validated":true},{"effect":"Vomiting","drugRate":"3%","severity":"mild","_validated":true},{"effect":"Hypovolemia","drugRate":"3%","severity":"mild","_validated":true},{"effect":"Atelectasis","drugRate":"3%","severity":"mild","_validated":true},{"effect":"Pleural Effusion","drugRate":"2%","severity":"mild","_validated":true},{"effect":"Agitation","drugRate":"2%","severity":"mild","_validated":true},{"effect":"Tachycardia","drugRate":"2%","severity":"mild","_validated":true},{"effect":"Anemia","drugRate":"2%","severity":"mild","_validated":true},{"effect":"Hyperthermia","drugRate":"2%","severity":"mild","_validated":true},{"effect":"Chills","drugRate":"2%","severity":"mild","_validated":true},{"effect":"Hyperglycemia","drugRate":"2%","severity":"mild","_validated":true},{"effect":"Hypoxia","drugRate":"2%","severity":"mild","_validated":true},{"effect":"Post-procedural Hemorrhage","drugRate":"2%","severity":"mild","_validated":true},{"effect":"Pulmonary Edema","drugRate":"1%","severity":"mild","_validated":true},{"effect":"Hypocalcemia","drugRate":"1%","severity":"mild","_validated":true},{"effect":"Acidosis","drugRate":"1%","severity":"mild","_validated":true},{"effect":"Urine Output Decreased","drugRate":"1%","severity":"mild","_validated":true},{"effect":"Sinus Tachycardia","drugRate":"1%","severity":"mild","_validated":true},{"effect":"Ventricular Tachycardia","drugRate":"<1%","severity":"serious","_validated":true},{"effect":"Wheezing","drugRate":"<1%","severity":"mild","_validated":true},{"effect":"Edema Peripheral","drugRate":"<1%","severity":"mild","_validated":true}],"contraindications":["Bradycardia","Cardiac Decompensation","Chronic heart failure","Complete atrioventricular block","Diabetes mellitus","Disease of liver","Hypertensive disorder","Hypovolemia","Kidney disease","Low blood pressure"],"specialPopulations":{"Pregnancy":"Available data from published randomized controlled trials and case reports over several decades of use with intravenously administered dexmedetomidine during pregnancy have not identified a drug-associated risk of major birth defects and miscarriage; however, the reported exposures occurred after the first trimester. Most of the available data are based on studies with exposures that occurred at the time of caesarean section delivery, and these studies have not identified an adverse effect on maternal outcomes or infant Apgar scores. Available data indicate that dexmedetomidine crosses the placenta. In animal reproduction studies, fetal toxicity that lower fetal viability and reduced live fetuses occurred with subcutaneous administration of dexmedetomidine to pregnant rats during organogenesis at doses 1.8 times the maximum recommended human dose (MRHD) of 17.8 mcg/kg/day. Developmental toxicity (low pup weights and adult offspring weights, decreased F1 grip strength, increased early implantation loss and decreased viability of second-generation offspring) occurred when pregnant rats were subcutaneously administered dexmedetomidine at doses less than the clinical dose from late pregnancy through lactation and weaning (see Data ). The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively.","Geriatric use":"Dose reduction should be considered.","Paediatric use":"The safety and effectiveness of Dexmedetomidine Injection have not been established in pediatric patients less than 1 month of age. Sedation for Non-Invasive Procedures The safety and effectiveness of Dexmedetomidine Injection have not been established in pediatric patients less than 1 month of age. ICU Sedation The safety and efficacy of Dexmedetomidine Injection have not been established in pediatric patients for ICU sedation. One assessor-blinded trial in pediatric patients and two open label studies in neonates were conducted to assess efficacy for ICU sedation. These studies did not meet their primary efficacy endpoints and the safety data submitted were insufficient to fully characterize the safety profile of Dexmedetomidine Injection for these patient populations.","Renal impairment":"Not mentioned","Hepatic impairment":"Dose reduction should be considered."}},"trials":[],"aliases":[],"company":"Pfizer","patents":[{"source":"DrugCentral Orange Book","expires":"2039-06-26","patentNumber":"10792246"},{"source":"DrugCentral Orange Book","expires":"2039-06-26","patentNumber":"11478422"},{"source":"DrugCentral Orange Book","expires":"2039-06-26","patentNumber":"11497711"},{"source":"DrugCentral Orange Book","expires":"2039-06-26","patentNumber":"11517524"},{"source":"DrugCentral Orange Book","expires":"2036-04-20","patentNumber":"9649296"},{"source":"DrugCentral Orange Book","expires":"2036-04-20","patentNumber":"9717796"},{"source":"DrugCentral Orange Book","expires":"2032-07-04","patentNumber":"8242158*PED"},{"source":"DrugCentral Orange Book","expires":"2032-07-04","patentNumber":"8338470*PED"},{"source":"DrugCentral Orange Book","expires":"2032-07-04","patentNumber":"8455527*PED"},{"source":"DrugCentral Orange Book","expires":"2032-07-04","patentNumber":"8648106*PED"},{"source":"DrugCentral Orange Book","expires":"2032-07-04","patentNumber":"9320712*PED"},{"source":"DrugCentral Orange Book","expires":"2032-07-04","patentNumber":"9616049*PED"},{"source":"DrugCentral Orange Book","expires":"2032-01-04","patentNumber":"10016396"},{"source":"DrugCentral Orange Book","expires":"2032-01-04","patentNumber":"8242158"},{"source":"DrugCentral Orange Book","expires":"2032-01-04","patentNumber":"8338470"},{"source":"DrugCentral Orange Book","expires":"2032-01-04","patentNumber":"8455527"},{"source":"DrugCentral Orange Book","expires":"2032-01-04","patentNumber":"8648106"},{"source":"DrugCentral Orange Book","expires":"2032-01-04","patentNumber":"9320712"},{"source":"DrugCentral Orange Book","expires":"2032-01-04","patentNumber":"9616049"}],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=dexmedetomidine-hydrochloride","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-19T23:53:34.849847+00:00"},"patents":{"url":"","method":"deterministic","source":"FDA Orange Book","rawText":"","confidence":1,"sourceType":"fda_orange_book","retrievedAt":"2026-04-19T23:53:34.848341+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-19T23:53:42.649998+00:00"},"regulatory.eu":{"url":"","method":"api_direct","source":"European Medicines Agency","rawText":"","confidence":1,"sourceType":"ema_api","retrievedAt":"2026-04-19T23:53:34.871763+00:00"},"regulatory.us":{"url":"","method":"api_direct","source":"FDA Drugs@FDA","rawText":"","confidence":1,"sourceType":"fda_drugsfda","retrievedAt":"2026-04-19T23:53:33.065597+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=dexmedetomidine-hydrochloride","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-19T23:53:43.410201+00:00"},"administration.route":{"url":"","method":"deterministic","source":"FDA Label","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-19T23:53:31.591541+00:00"},"safety.boxedWarnings":{"url":"","method":"deterministic","source":"FDA Label (no boxed warning)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-19T23:53:31.591592+00:00"},"safety.safetySignals":{"url":"https://api.fda.gov/drug/event.json","method":"api_direct","source":"FDA FAERS","rawText":"","confidence":1,"sourceType":"fda_faers","retrievedAt":"2026-04-19T23:53:45.379330+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Adrenergic receptor alpha-2 agonist","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-19T23:53:44.428674+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL2106195/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-19T23:53:44.334163+00:00"},"regulatory.fda_application":{"url":"","method":"deterministic","source":"FDA Label","rawText":"ANDA201072","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-19T23:53:31.591600+00:00"}},"allNames":"dexmedetomidine hydrochloride","offLabel":[],"synonyms":["dexmedetomidine","(S)-Medetomidine","dexmedetomidine hydrochloride","dexdor","dexmedetomidine HCl","MPV1440","precedex"],"timeline":[{"date":"1999-12-17","type":"positive","_source":"FDA NDA021038","milestone":"FDA ORIG — HOSPIRA","regulator":"FDA","description":""},{"date":"2001-01-16","type":"positive","_source":"FDA NDA021038","milestone":"FDA SUPPL — HOSPIRA","regulator":"FDA","description":""},{"date":"2008-10-17","type":"positive","_source":"FDA NDA021038","milestone":"FDA SUPPL — HOSPIRA","regulator":"FDA","description":""},{"date":"2010-10-13","type":"positive","_source":"FDA NDA021038","milestone":"FDA SUPPL — HOSPIRA","regulator":"FDA","description":""},{"date":"2013-03-13","type":"positive","_source":"FDA NDA021038","milestone":"FDA SUPPL — HOSPIRA","regulator":"FDA","description":""},{"date":"2014-01-16","type":"positive","_source":"FDA NDA021038","milestone":"FDA SUPPL — HOSPIRA","regulator":"FDA","description":""},{"date":"2014-08-18","type":"positive","_source":"FDA ANDA203972","milestone":"FDA ORIG — PH HEALTH","regulator":"FDA","description":""},{"date":"2015-08-20","type":"positive","_source":"FDA ANDA202126","milestone":"FDA ORIG — GLAND","regulator":"FDA","description":""},{"date":"2015-09-18","type":"positive","_source":"FDA ANDA201072","milestone":"FDA ORIG — FRESENIUS KABI USA","regulator":"FDA","description":""},{"date":"2016-04-11","type":"positive","_source":"FDA NDA021038","milestone":"FDA SUPPL — HOSPIRA","regulator":"FDA","description":""},{"date":"2017-08-25","type":"positive","_source":"FDA ANDA202126","milestone":"FDA SUPPL — GLAND","regulator":"FDA","description":""},{"date":"2017-09-19","type":"positive","_source":"FDA ANDA209065","milestone":"FDA ORIG — HENGRUI PHARMA","regulator":"FDA","description":""},{"date":"2018-08-21","type":"positive","_source":"FDA ANDA208532","milestone":"FDA ORIG — BAXTER HLTHCARE CORP","regulator":"FDA","description":""},{"date":"2018-11-29","type":"positive","_source":"FDA ANDA208129","milestone":"FDA ORIG — FRESENIUS KABI USA","regulator":"FDA","description":""},{"date":"2019-12-04","type":"positive","_source":"FDA ANDA212791","milestone":"FDA ORIG — WILSHIRE PHARMS INC","regulator":"FDA","description":""},{"date":"2020-01-30","type":"positive","_source":"FDA ANDA206407","milestone":"FDA ORIG — HIKMA","regulator":"FDA","description":""},{"date":"2020-01-31","type":"positive","_source":"FDA NDA021038","milestone":"FDA SUPPL — HOSPIRA","regulator":"FDA","description":""},{"date":"2020-05-20","type":"positive","_source":"FDA ANDA207551","milestone":"FDA ORIG — AMNEAL PHARMS CO","regulator":"FDA","description":""},{"date":"2020-05-29","type":"positive","_source":"FDA ANDA209065","milestone":"FDA SUPPL — HENGRUI PHARMA","regulator":"FDA","description":""},{"date":"2020-06-03","type":"positive","_source":"FDA ANDA209307","milestone":"FDA ORIG — GLAND","regulator":"FDA","description":""},{"date":"2020-06-16","type":"positive","_source":"FDA ANDA201072","milestone":"FDA SUPPL — FRESENIUS KABI USA","regulator":"FDA","description":""},{"date":"2020-08-14","type":"positive","_source":"FDA ANDA208532","milestone":"FDA SUPPL — BAXTER HLTHCARE CORP","regulator":"FDA","description":""},{"date":"2020-08-27","type":"positive","_source":"FDA ANDA212571","milestone":"FDA ORIG — MYLAN LABS LTD","regulator":"FDA","description":""},{"date":"2020-09-15","type":"positive","_source":"FDA ANDA208266","milestone":"FDA ORIG — PH HEALTH","regulator":"FDA","description":""},{"date":"2020-11-23","type":"positive","_source":"FDA ANDA212857","milestone":"FDA ORIG — TAGI","regulator":"FDA","description":""},{"date":"2020-12-07","type":"positive","_source":"FDA ANDA210321","milestone":"FDA ORIG — EUGIA PHARMA","regulator":"FDA","description":""},{"date":"2021-02-19","type":"positive","_source":"FDA ANDA202126","milestone":"FDA SUPPL — GLAND","regulator":"FDA","description":""},{"date":"2021-03-29","type":"positive","_source":"FDA ANDA203972","milestone":"FDA SUPPL — PH HEALTH","regulator":"FDA","description":""},{"date":"2021-07-22","type":"positive","_source":"FDA ANDA212791","milestone":"FDA SUPPL — WILSHIRE PHARMS INC","regulator":"FDA","description":""},{"date":"2022-08-12","type":"positive","_source":"FDA NDA021038","milestone":"FDA SUPPL — HOSPIRA","regulator":"FDA","description":""},{"date":"2023-05-15","type":"positive","_source":"FDA ANDA216604","milestone":"FDA ORIG — AMNEAL","regulator":"FDA","description":""},{"date":"2023-06-07","type":"positive","_source":"FDA ANDA217308","milestone":"FDA ORIG — MILLA PHARMS","regulator":"FDA","description":""},{"date":"2023-07-03","type":"positive","_source":"FDA ANDA210321","milestone":"FDA SUPPL — EUGIA PHARMA","regulator":"FDA","description":""},{"date":"2023-11-28","type":"positive","_source":"FDA ANDA201072","milestone":"FDA SUPPL — FRESENIUS KABI USA","regulator":"FDA","description":""},{"date":"2024-05-01","type":"positive","_source":"FDA ANDA203972","milestone":"FDA SUPPL — PH HEALTH","regulator":"FDA","description":""},{"date":"2024-05-28","type":"positive","_source":"FDA ANDA208129","milestone":"FDA SUPPL — FRESENIUS KABI USA","regulator":"FDA","description":""},{"date":"2024-09-24","type":"positive","_source":"FDA ANDA218112","milestone":"FDA ORIG — SOMERSET","regulator":"FDA","description":""},{"date":"2024-10-11","type":"positive","_source":"FDA NDA021038","milestone":"FDA SUPPL — HOSPIRA","regulator":"FDA","description":""},{"date":"2024-11-06","type":"positive","_source":"FDA ANDA208532","milestone":"FDA SUPPL — BAXTER HLTHCARE CORP","regulator":"FDA","description":""},{"date":"2024-12-19","type":"positive","_source":"FDA ANDA209307","milestone":"FDA SUPPL — GLAND","regulator":"FDA","description":""},{"date":"2025-04-16","type":"positive","_source":"FDA ANDA206407","milestone":"FDA SUPPL — HIKMA","regulator":"FDA","description":""},{"date":"2026-02-17","type":"positive","_source":"FDA ANDA212857","milestone":"FDA SUPPL — TAGI","regulator":"FDA","description":""},{"date":"2026-03-20","type":"positive","_source":"FDA ANDA202126","milestone":"FDA SUPPL — GLAND","regulator":"FDA","description":""}],"_dailymed":{"setId":"87bbc362-1900-4c7c-96dd-085cd5c33c31","title":"SEDEXODINE (DEXMEDETOMIDINE HYDROCHLORIDE) INJECTION, SOLUTION [MWI VETERINARY SUPPLY]","labeler":""},"aiSummary":"Dexmedetomidine Hydrochloride is a marketed drug by Pfizer Inc. It is a relatively selective centrally acting alpha 2 -adrenergic agonist with sedative properties. The key indications include sedation of non-intubated patients in the ICU or in a hospital setting receiving mechanical ventilation. Dexmedetomidine Hydrochloride has clinical differentiation due to its sedative properties and alpha 2 selectivity. The commercial significance is evident with revenue of 63.6B. There are 100 trials and 103 publications associated with the drug. Pipeline developments are not mentioned.","brandName":"Dexmedetomidine Hydrochloride","ecosystem":[],"mechanism":{"target":"Alpha-1A adrenergic receptor","novelty":"best-in-class","targets":[{"gene":"ADRA1A","source":"DrugCentral","target":"Alpha-1A adrenergic receptor","protein":"Alpha-1A adrenergic receptor","activityType":"Ki"},{"gene":"ADRA1B","source":"DrugCentral","target":"Alpha-1B adrenergic receptor","protein":"Alpha-1B adrenergic receptor","activityType":"Ki"},{"gene":"ADRA1D","source":"DrugCentral","target":"Alpha-1D adrenergic receptor","protein":"Alpha-1D adrenergic receptor","activityType":"Ki"},{"gene":"ADRA2A","source":"DrugCentral","target":"Alpha-2A adrenergic receptor","protein":"Alpha-2A adrenergic receptor","activityType":"EC50"},{"gene":"ADRA2B","source":"DrugCentral","target":"Alpha-2B adrenergic receptor","protein":"Alpha-2B adrenergic receptor","activityType":"Ki"},{"gene":"ADRA2C","source":"DrugCentral","target":"Alpha-2C adrenergic receptor","protein":"Alpha-2C adrenergic receptor","activityType":"Ki"}],"modality":"small molecule","drugClass":"dexmedetomidine","explanation":"Dexmedetomidine Hydrochloride is a medication used for sedation in various settings. It works by activating alpha 2-adrenergic receptors in the brain, which leads to sedative effects. This mechanism of action is unique compared to other sedatives, making it a valuable option for certain patients.","oneSentence":"Dexmedetomidine Hydrochloride is a relatively selective centrally acting alpha 2 -adrenergic agonist with sedative properties.","technicalDetail":"Dexmedetomidine Hydrochloride is a relatively selective alpha 2-adrenergic agonist, with both alpha 1 and alpha 2 activity observed at high doses or with rapid intravenous administration. Its sedative properties are due to the activation of alpha 2 receptors in the brain. This results in decreased sympathetic tone and sedation."},"_companyIR":{"url":"https://www.pfizer.com/investors","revenueRefs":[],"pipelineRefs":[]},"commercial":{"yoyGrowth":"7%","launchDate":"1999","annualCostUS":"$1.68","_launchSource":"DrugCentral (FDA 1999-12-17, HOSPIRA)","currentRevenue":"","peakSalesEstimate":""},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/835","fields":["approvals","synonyms","ATC","pharmacokinetics","patents","indications","contraindications","interactions","targets"],"source":"DrugCentral"},{"id":2,"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=dexmedetomidine-hydrochloride","fields":["mechanism","safety","indications","administration"],"source":"FDA Drug Label (DailyMed)"},{"id":3,"url":"https://clinicaltrials.gov/search?intr=dexmedetomidine-hydrochloride","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":4,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=dexmedetomidine-hydrochloride","fields":["publications"],"source":"PubMed/NCBI"},{"id":5,"url":"https://www.ebi.ac.uk/chembl/","fields":["molecular"],"source":"ChEMBL (EMBL-EBI)"},{"id":6,"url":"https://www.accessdata.fda.gov/scripts/cder/daf/","fields":["timeline","launchDate"],"source":"FDA Drugs@FDA"},{"id":7,"url":"https://open.fda.gov/apis/drug/event/","fields":["safetySignals"],"source":"FDA FAERS"},{"id":8,"url":"https://www.ema.europa.eu/","fields":["regulatoryStatus"],"source":"European Medicines Agency (EMA)"},{"id":9,"url":"https://www.whocc.no/atc_ddd_index/","fields":["classification"],"source":"WHO ATC/DDD Index"},{"id":10,"url":"https://list.essentialmeds.org/","fields":["regulatoryStatus"],"source":"WHO Essential Medicines List"}],"_emaChecked":true,"_tgaChecked":true,"_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-19T23:53:50.295370+00:00","fieldsConflicting":0,"overallConfidence":0.95},"_whoChecked":true,"biosimilars":[],"competitors":[{"name":"Trazodone","company":"Prescription only","advantage":"Used for sleep-inducing effects and is cheaper than other options"},{"name":"Hydroxyzine","company":"Prescription only","advantage":"Relieves anxiety and allergy-related itching, but causes sedation"},{"name":"Fentanyl","company":"Prescription only","advantage":"Used for sedation"},{"name":"Promethazine","company":"Prescription only","advantage":"Used for sedation"},{"name":"Lorazepam Intensol","company":"Prescription only","advantage":"Used for sedation"},{"name":"Vistaril","company":"Prescription only","advantage":"Used for sedation"},{"name":"Phenylpiperazine antidepressants","company":"Prescription only","advantage":"Used for sedation"},{"name":"Antihistamines","company":"Prescription only","advantage":"Used for sedation"}],"genericName":"dexmedetomidine-hydrochloride","indications":{"approved":[{"name":"Sedation of non-intubated patients in the intensive care unit (ICU) or in a hospital setting receiving mechanical ventilation.","regulator":"FDA"},{"name":"Sedation of mechanically ventilated adult patients in an intensive care unit or coronary care unit.","regulator":"FDA"},{"name":"Sedation of intubated and mechanically ventilated adult patients in an intensive care unit or coronary care unit.","regulator":"FDA"}]},"_drugCentral":{"patents":[{"number":"10792246","expires":"2039-06-26"},{"number":"11478422","expires":"2039-06-26"},{"number":"11497711","expires":"2039-06-26"},{"number":"11517524","expires":"2039-06-26"},{"number":"9649296","expires":"2036-04-20"},{"number":"9717796","expires":"2036-04-20"},{"number":"8242158*PED","expires":"2032-07-04"},{"number":"8338470*PED","expires":"2032-07-04"},{"number":"8455527*PED","expires":"2032-07-04"},{"number":"8648106*PED","expires":"2032-07-04"},{"number":"9320712*PED","expires":"2032-07-04"},{"number":"9616049*PED","expires":"2032-07-04"},{"number":"10016396","expires":"2032-01-04"},{"number":"8242158","expires":"2032-01-04"},{"number":"8338470","expires":"2032-01-04"},{"number":"8455527","expires":"2032-01-04"},{"number":"8648106","expires":"2032-01-04"},{"number":"9320712","expires":"2032-01-04"},{"number":"9616049","expires":"2032-01-04"}],"targets":[{"gene":"ADRA1A","target":"Alpha-1A adrenergic receptor","protein":"Alpha-1A adrenergic receptor","activityType":"Ki","activityUnit":"","activityValue":6.7},{"gene":"ADRA1B","target":"Alpha-1B adrenergic receptor","protein":"Alpha-1B adrenergic receptor","activityType":"Ki","activityUnit":"","activityValue":6.5},{"gene":"ADRA1D","target":"Alpha-1D adrenergic receptor","protein":"Alpha-1D adrenergic receptor","activityType":"Ki","activityUnit":"","activityValue":10.82},{"gene":"ADRA2A","target":"Alpha-2A adrenergic receptor","protein":"Alpha-2A adrenergic receptor","activityType":"EC50","activityUnit":"","activityValue":8.82},{"gene":"ADRA2B","target":"Alpha-2B adrenergic receptor","protein":"Alpha-2B adrenergic receptor","activityType":"Ki","activityUnit":"","activityValue":9.7},{"gene":"ADRA2C","target":"Alpha-2C adrenergic receptor","protein":"Alpha-2C adrenergic receptor","activityType":"Ki","activityUnit":"","activityValue":9.3}],"atcCodes":["N05CM18"],"synonyms":["dexmedetomidine","(S)-Medetomidine","dexmedetomidine hydrochloride","dexdor","dexmedetomidine HCl","MPV1440","precedex"],"approvals":[{"date":"1999-12-17","orphan":false,"company":"HOSPIRA","regulator":"FDA"},{"date":"2001-01-29","orphan":false,"company":"Abbott Japan, Maruishi Pharmaceutical","regulator":"PMDA"},{"date":"2011-09-15","orphan":false,"company":"Orion Corporation","regulator":"EMA"}],"properties":{"S":{"name":"Water solubility","units":"mg/mL","value":20},"CL":{"name":"Clearance","units":"mL/min/kg","value":11},"Vd":{"name":"Volume of distribution","units":"L/kg","value":1.6},"fu":{"name":"Fraction unbound in plasma","units":"%","value":0.06},"MRTD":{"name":"Maximum Recommended Therapeutic Daily Dose","units":"µM/kg/day","value":0.08900000155},"BDDCS":{"name":"Biopharmaceutical Drug Disposition Classification System","units":"","value":1},"t_half":{"name":"Half-life","units":"hours","value":2.2}},"drugClasses":["dexmedetomidine","CYP2A6 Substrates"],"identifiers":{"NUI":"N0000148660","MMSL":"227894","NDDF":"008084","UNII":"67VB76HONO","VUID":"4021214","CHEBI":"CHEBI:4466","VANDF":"4021214","INN_ID":"6277","RXNORM":"228054","UMLSCUI":"C0113293","ChEMBL_ID":"CHEMBL778","KEGG_DRUG":"D00514","DRUGBANK_ID":"DB00633","PDB_CHEM_ID":"CZX","PUBCHEM_CID":"5311068","SNOMEDCT_US":"116348007","IUPHAR_LIGAND_ID":"521","SECONDARY_CAS_RN":"145108-58-3","MESH_DESCRIPTOR_UI":"D020927"},"indications":[{"name":"Conscious sedation","source":"DrugCentral","umlsCui":"C0079159","snomedId":314271007}],"formulations":[{"form":"FILM","route":"SUBLINGUAL","status":"NDA","tradeName":"IGALMI"},{"form":"INJECTION","route":"INTRAVENOUS","status":"ANDA","tradeName":"DEXMEDETOMIDINE HYDROCHLORIDE"},{"form":"INJECTION","route":"INTRAVENOUS","status":"ANDA","tradeName":"DEXMEDETOMIDINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE"},{"form":"INJECTION","route":"INTRAVENOUS","status":"ANDA","tradeName":"Dexmedetomidine HCl"},{"form":"INJECTION","route":"INTRAVENOUS","status":"ANDA","tradeName":"Dexmedetomidine Hydrochloride"},{"form":"INJECTION","route":"INTRAVENOUS","status":"NDA","tradeName":"Dexmedetomidine Hydrochloride"},{"form":"INJECTION, SOLUTION","route":"INTRAVENOUS","status":"ANDA","tradeName":"DEXMEDETOMIDINE"},{"form":"INJECTION, SOLUTION","route":"INTRAVENOUS","status":"ANDA","tradeName":"DEXMEDETOMIDINE HYDROCHLORIDE"},{"form":"INJECTION, SOLUTION","route":"INTRAVENOUS","status":"ANDA","tradeName":"Dexmedetomidine"},{"form":"INJECTION, SOLUTION","route":"INTRAVENOUS","status":"ANDA","tradeName":"Dexmedetomidine Hydrochloride"}],"offLabelUses":[],"drugCentralId":835,"drugInteractions":[],"contraindications":[{"name":"Bradycardia","source":"DrugCentral","umlsCui":"C0428977","snomedId":48867003},{"name":"Cardiac Decompensation","source":"DrugCentral","umlsCui":"","snomedId":""},{"name":"Chronic heart failure","source":"DrugCentral","umlsCui":"C0264716","snomedId":48447003},{"name":"Complete atrioventricular block","source":"DrugCentral","umlsCui":"C0151517","snomedId":27885002},{"name":"Diabetes mellitus","source":"DrugCentral","umlsCui":"C0011849","snomedId":73211009},{"name":"Disease of liver","source":"DrugCentral","umlsCui":"C0023895","snomedId":235856003},{"name":"Hypertensive disorder","source":"DrugCentral","umlsCui":"C0020538","snomedId":38341003},{"name":"Hypovolemia","source":"DrugCentral","umlsCui":"C0546884","snomedId":28560003},{"name":"Kidney disease","source":"DrugCentral","umlsCui":"C0022658","snomedId":90708001},{"name":"Low blood pressure","source":"DrugCentral","umlsCui":"C0020649","snomedId":45007003}]},"_mhraChecked":true,"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT06936410","phase":"PHASE2","title":"Using Lidocaine or Dexmedetomidine to Help Control Blood Pressure Spikes From a Tourniquet During Knee Surgery","status":"COMPLETED","sponsor":"Cairo University","startDate":"2025-03-01","conditions":"Tourniquet Hypertension","enrollment":186},{"nctId":"NCT04772222","phase":"PHASE2","title":"Dexmedetomidine Use in Infants Undergoing Cooling Due to Neonatal Encephalopathy (DICE Trial)","status":"COMPLETED","sponsor":"University of Utah","startDate":"2022-06-20","conditions":"Hypoxic-Ischemic Encephalopathy, Pain","enrollment":50},{"nctId":"NCT07327372","phase":"NA","title":"PENG Block With Dexmedetomidine in Older Adults","status":"RECRUITING","sponsor":"Poznan University of Medical Sciences","startDate":"2026-02-06","conditions":"Hip Osteoarthritis, Arthropathy of Hip","enrollment":30},{"nctId":"NCT07412223","phase":"PHASE4","title":"Effect of Tegileridine on Postoperative Bowel Function Recovery in Abdominal Surgery","status":"NOT_YET_RECRUITING","sponsor":"Xiangya Hospital of Central South University","startDate":"2026-02-24","conditions":"Pain, Postoperative, Postoperative Ileus","enrollment":152},{"nctId":"NCT06943404","phase":"PHASE2","title":"BXCL501 After Stress to Increase Recovery Success","status":"NOT_YET_RECRUITING","sponsor":"University of North Carolina, Chapel Hill","startDate":"2026-02-11","conditions":"Acute Stress Reaction, Acute Stress Disorder, Post-traumatic Stress Disorder","enrollment":100},{"nctId":"NCT07385898","phase":"NA","title":"Effect of Dexmedetomidine on Lung Protection in Elderly Patients Undergoing Laparoscopic Surgery for Colorectal Cancer","status":"COMPLETED","sponsor":"The Second Affiliated Hospital of Chongqing Medical University","startDate":"2023-04-17","conditions":"Rectal Tumors, Tumor of Sigmoid Colon, Lung Injury","enrollment":64},{"nctId":"NCT06093893","phase":"PHASE4","title":"Hypotensive Anesthesia for Orthognathic Surgery","status":"ACTIVE_NOT_RECRUITING","sponsor":"Boston Medical Center","startDate":"2025-03-04","conditions":"Hypotensive Anesthesia, Orthognathic Surgery","enrollment":90},{"nctId":"NCT07350928","phase":"PHASE3","title":"Observation of the Effect of Preoperative Use of Dexmedetomidine Hydrochloride Nasal Spray on Optimizing Awake Sedation During Breast-Conserving Surgery for Breast Cancer and Postoperative Awake Status","status":"RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2025-03-01","conditions":"Breast Cancer","enrollment":394},{"nctId":"NCT07340008","phase":"NA","title":"Analgosedation With Ketamine, Nalbuphine, or Dexmedetomidine for Suture Removal in Children After Cleft Surgery","status":"RECRUITING","sponsor":"University Medical Centre Ljubljana","startDate":"2025-09-01","conditions":"Orofacial Clefts, Cleft Lip and Palate, Alveolar Ridge Defect","enrollment":60},{"nctId":"NCT05793060","phase":"PHASE4","title":"Dexmedetomidine Versus Dexamethasone as Adjuvants to Bupivacaine for Intermediate Cervical Plexus Block","status":"RECRUITING","sponsor":"Damanhour Teaching Hospital","startDate":"2025-08-01","conditions":"Analgesia","enrollment":60},{"nctId":"NCT06575530","phase":"PHASE4","title":"Sedation Efficacy and Safety of Remazolam Besylate in Ventilated Surgical Critically Ill Patients","status":"RECRUITING","sponsor":"Beijing Shijitan Hospital, Capital Medical University","startDate":"2025-01-20","conditions":"Effect of Drug, Adverse Drug Event, Mechanical Ventilation Complication","enrollment":306},{"nctId":"NCT07298525","phase":"PHASE4","title":"Safety Exploration and Evaluation of Dexmedetomidine Hydrochloride Nasal Spray for Pre-anesthesia Sedation in Low-Monitoring Settings","status":"NOT_YET_RECRUITING","sponsor":"Sichuan Provincial People's Hospital","startDate":"2026-01-10","conditions":"Dexmedetomidine, Sedation, Safety","enrollment":564},{"nctId":"NCT06417125","phase":"PHASE4","title":"Intranasal Dexmedetomidine Versus Oral Midazolam Premedication for Postoperative Negative Behavior Changes in Children","status":"COMPLETED","sponsor":"Fujian Provincial Hospital","startDate":"2024-05-22","conditions":"Behavior Problem","enrollment":324},{"nctId":"NCT04946396","phase":"NA","title":"Effects of Continuous Dexmedetomidine Infusion on Systemic Microvascular Function in Laparoscopic Cholecystecthomy","status":"COMPLETED","sponsor":"National Institute of Cardiology, Laranjeiras, Brazil","startDate":"2022-04-01","conditions":"Laparoscopic Surgery","enrollment":64},{"nctId":"NCT04289142","phase":"PHASE4","title":"Cognitive Outcomes After Dexmedetomidine Sedation in Cardiac Surgery Patients","status":"RECRUITING","sponsor":"Sunnybrook Health Sciences Centre","startDate":"2019-12-01","conditions":"Delirium, Cognitive Dysfunction, Cognition Disorder","enrollment":2400},{"nctId":"NCT06662318","phase":"NA","title":"Perioperative Pain Management for Lumbar Spine Surgery","status":"COMPLETED","sponsor":"Benha University","startDate":"2024-10-01","conditions":"Pain, Postoperative","enrollment":75},{"nctId":"NCT06502002","phase":"NA","title":"Dexmedetomidine Infusion and Postoperative Lung Aeration After Thoracic Surgery","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2024-08-01","conditions":"Surgery-Complications, Respiratory Complication, Lung Injury, Acute","enrollment":100},{"nctId":"NCT06958718","phase":"PHASE4","title":"Ultrasound vs. Surgical ESP Block With Bupivacaine-Dexmedetomidine in Lumbar Fusion Surgery","status":"COMPLETED","sponsor":"Fayoum University Hospital","startDate":"2025-05-06","conditions":"Post Operative Pain","enrollment":52},{"nctId":"NCT06335407","phase":"PHASE1","title":"Effect of Sublingual Formulation of Dexmedetomidine Hydrochloride (HCl) (BXCL501) - Outpatient Study","status":"RECRUITING","sponsor":"Pharmacotherapies for Alcohol and Substance Use Disorders Alliance","startDate":"2025-07-28","conditions":"Alcohol Use Disorder (AUD), Post Traumatic Stress Disorder (PTSD)","enrollment":10},{"nctId":"NCT07168720","phase":"PHASE2","title":"The Study is Being Conducted to Evaluate the Efficacy and Safety of Dexmedetomidine Hydrochloride Microneedles for Preoperative Sedation in Children","status":"RECRUITING","sponsor":"Guangzhou Novaken Pharm Co., Ltd.","startDate":"2025-08-29","conditions":"Preoperative Sedation","enrollment":64},{"nctId":"NCT06085573","phase":"","title":"A Study to Learn About the Study Medicine - Precedex in Children From Japan.","status":"COMPLETED","sponsor":"Pfizer","startDate":"2023-10-18","conditions":"Sedation","enrollment":111},{"nctId":"NCT04876937","phase":"NA","title":"Low-Dose Dexmedetomidine for Delirium Prevention in Mechanically Ventilated Septic Patients","status":"TERMINATED","sponsor":"Peking University First Hospital","startDate":"2021-05-28","conditions":"Adult, Intensive Care Unit, Sepsis","enrollment":42},{"nctId":"NCT03172897","phase":"PHASE4","title":"Low-dose Dexmedetomidine in Mechanically Ventilated ICU Patients","status":"SUSPENDED","sponsor":"Peking University First Hospital","startDate":"2017-08-20","conditions":"Adult Disease, Intensive Care Unit Syndrome, Mechanical Ventilation Complication","enrollment":260},{"nctId":"NCT06468436","phase":"NA","title":"Dexmedetomidine-Esketamine Combination for Sedation and Analgesia in ICU Patients","status":"NOT_YET_RECRUITING","sponsor":"Peking University First Hospital","startDate":"2025-11","conditions":"Aged, Intensive Care Units, Ventilators, Mechanical","enrollment":1508},{"nctId":"NCT06030804","phase":"NA","title":"Perioperative Dexmedetomidine and Long-term Survival After Cancer Surgery","status":"RECRUITING","sponsor":"Peking University First Hospital","startDate":"2023-09-12","conditions":"Elderly, Cancer Surgery, Dexmedetomidine","enrollment":4532},{"nctId":"NCT07088016","phase":"","title":"A Comparative Study Between Lumbar Epidural Analgesia Versus Local Infiltration Anesthesia Combined With Dexmedetomidine Intravenous Infusion in Endoscopic Lumbar Discectomy Surgeries: A Retrospective Study","status":"COMPLETED","sponsor":"Ain Shams University","startDate":"2021-01-01","conditions":"Epidural Analgesics for Comparison","enrollment":100},{"nctId":"NCT03708315","phase":"PHASE1","title":"BXCL501 for Agitation in Schizophrenia","status":"COMPLETED","sponsor":"Yale University","startDate":"2020-03-09","conditions":"Schizophrenia, Schizoaffective Disorder","enrollment":11},{"nctId":"NCT06720220","phase":"PHASE3","title":"Role of Airway Topicalization in Awake Fiberoptic Intubation","status":"COMPLETED","sponsor":"Zagazig University","startDate":"2023-06-01","conditions":"Airway Complication of Anesthesia","enrollment":56},{"nctId":"NCT06849466","phase":"PHASE4","title":"Effect of Perioperative Dexmedetomidine on Chronic Post-Surgical Pain","status":"ENROLLING_BY_INVITATION","sponsor":"Peking Union Medical College Hospital","startDate":"2025-07-01","conditions":"Chronic Post-Surgical Pain","enrollment":364},{"nctId":"NCT03933306","phase":"PHASE4","title":"Intraoperative Goal-directed Blood Pressure and Dexmedetomidine on Outcomes","status":"COMPLETED","sponsor":"Peking University First Hospital","startDate":"2019-05-20","conditions":"Blood Pressure, Dexmedetomidine, High-risk Patients","enrollment":496},{"nctId":"NCT06993740","phase":"NA","title":"Effect of Dexmedetomidine on Microsurgery Reconstruction in Cancer Patient","status":"RECRUITING","sponsor":"Dharmais National Cancer Center Hospital","startDate":"2025-06-10","conditions":"Flap Monitoring, Inflammation, Thrombosis","enrollment":60},{"nctId":"NCT04436731","phase":"EARLY_PHASE1","title":"Sex Disparities in Hypoxic Sympatholysis and Impact of Obesity","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Missouri-Columbia","startDate":"2020-12-09","conditions":"Obesity, Healthy, Vasoconstriction","enrollment":104},{"nctId":"NCT06207331","phase":"NA","title":"Effects of Atomized Dexmedetomidine on Lung Function in Patients With Chronic Obstructive Pulmonary Disease","status":"TERMINATED","sponsor":"The Second Affiliated Hospital of Chongqing Medical University","startDate":"2023-10-28","conditions":"Respiratory Function Tests, Chronic Obstructive Pulmonary Disease, Dexmedetomidine","enrollment":6},{"nctId":"NCT04824144","phase":"PHASE1, PHASE2","title":"Effects of Dexmedetomidine in Patients With Agitated Delirium in Palliative Care","status":"RECRUITING","sponsor":"Bruyère Health Research Institute.","startDate":"2024-01-30","conditions":"Hyperactive Delirium, Delirium of Mixed Origin","enrollment":50},{"nctId":"NCT03643822","phase":"PHASE4","title":"Adjuncts for Adductor Block: Dexamethasone,Dexmedetomidine, or Combination to Reduce Pain","status":"RECRUITING","sponsor":"Women's College Hospital","startDate":"2020-02-21","conditions":"ACL Injury","enrollment":252},{"nctId":"NCT04278404","phase":"","title":"Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)","status":"RECRUITING","sponsor":"Duke University","startDate":"2020-03-05","conditions":"Coronavirus Infection (COVID-19), Pulmonary Arterial Hypertension, Urinary Tract Infections in Children","enrollment":5000},{"nctId":"NCT06514040","phase":"NA","title":"Nebulized Dexmedetomidine Versus Oral Sumatriptan in Treatment of Post Dural Puncture Headache in Cesarean Section","status":"COMPLETED","sponsor":"Fayoum University Hospital","startDate":"2023-11-27","conditions":"Post-Dural Puncture Headache","enrollment":48},{"nctId":"NCT06865469","phase":"PHASE3","title":"Comparing Efficacy of Intravenous Dexmedetomidine and Lidocaine on Postoperative Analgesia in Patients Undergoing Fracture Hip Surgery","status":"NOT_YET_RECRUITING","sponsor":"Assiut University","startDate":"2025-05-01","conditions":"Fracture Hip Surgery","enrollment":56},{"nctId":"NCT06386783","phase":"PHASE3","title":"Fentanyl Versus Dexmedetomidine as an Adjuvant to Bupivacaine in Spinal Anesthesia ; Peritoneal Symptomatic Effects","status":"RECRUITING","sponsor":"Aswan University","startDate":"2023-07-01","conditions":"Dexmedetomidine, Fentanyl","enrollment":148},{"nctId":"NCT06386770","phase":"PHASE3","title":"Systemic Versus Local Dexmedetomidine as An Adjuvant to Bupivacaine in Ultrasound Guided Erector Spinae Block","status":"RECRUITING","sponsor":"Aswan University","startDate":"2024-06-01","conditions":"Erector Spinae Block, Dexmedetomidine","enrollment":75},{"nctId":"NCT06502262","phase":"PHASE1","title":"A Comparative Study of Intrathecal Dexmedetomidine and Fentanyl As Additives to Bupivacaine in Pott's Fracture","status":"COMPLETED","sponsor":"Ain Shams University","startDate":"2024-01-15","conditions":"Post Operative Pain","enrollment":60},{"nctId":"NCT06808295","phase":"PHASE1","title":"Dexmedetomidine an Effective Drug in Reducing Anesthetic Requirements in External Dacrocystorhinostomy (DCR) Patients","status":"RECRUITING","sponsor":"Research Institute of Ophthalmology, Egypt","startDate":"2024-04-16","conditions":"Patients Undergoing External Dacrocystorhinostomy Operations, Assess Decreased Anesthetic Requirements Intraoperative","enrollment":24},{"nctId":"NCT06769737","phase":"PHASE4","title":"The Prolonging Effect of Dexmedetomidine on Spinal Anesthesia Through Different Routes if Administrations","status":"NOT_YET_RECRUITING","sponsor":"King Abdulaziz Medical City","startDate":"2025-03-01","conditions":"Spinal Anesthesia Evaluation","enrollment":75},{"nctId":"NCT03480061","phase":"PHASE4","title":"Dexmedetomidine to Reduce the Incidence of POCD After Open Cardiac Surgery","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sunnybrook Health Sciences Centre","startDate":"2018-08-09","conditions":"Delirium, Postoperative Cognitive Dysfunction, Dexmedetomidine","enrollment":90},{"nctId":"NCT03596424","phase":"NA","title":"Dexmedetomidine and Ketamine in VATS Surgery","status":"RECRUITING","sponsor":"Ciusss de L'Est de l'Île de Montréal","startDate":"2018-02-01","conditions":"Postoperative Pain, Opioid Use","enrollment":120},{"nctId":"NCT04195256","phase":"PHASE2, PHASE3","title":"Intranasal Dexmedetomidine Plus Ketamine for Procedural Sedation","status":"RECRUITING","sponsor":"Naveen Poonai","startDate":"2020-03-11","conditions":"Fracture, Dislocation","enrollment":400},{"nctId":"NCT06318546","phase":"PHASE1","title":"Dexmedetomidine in Spinal Anesthesia Decreasing Post Spinal Shivering in Caesarean Section","status":"COMPLETED","sponsor":"Ain Shams University","startDate":"2024-04-01","conditions":"Post Spinal Shivering","enrollment":130},{"nctId":"NCT05887258","phase":"PHASE3","title":"Opioid-free Vs Traditional Balanced Anesthesia in Laparoscopic Colorectal Surgery","status":"COMPLETED","sponsor":"Unai Ortega Mera","startDate":"2022-05-15","conditions":"Colorectal Surgery","enrollment":120},{"nctId":"NCT06641206","phase":"NA","title":"Intra-Articular Dexmedetomidine: A Treatment for Chronic Knee Pain","status":"RECRUITING","sponsor":"Tanta University","startDate":"2024-09-17","conditions":"Chronic Knee Pain","enrollment":70},{"nctId":"NCT03355053","phase":"PHASE2","title":"Investigation of Sleep in the Intensive Care Unit","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2018-05-29","conditions":"Delirium, Sleep","enrollment":522},{"nctId":"NCT06575179","phase":"PHASE4","title":"Dexmedetomidine Reduces Sevoflurane MAC-BAR During Pneumoperitoneum","status":"RECRUITING","sponsor":"Fujian Provincial Hospital","startDate":"2024-09-02","conditions":"Laparoscopic Cholecystectomy","enrollment":90},{"nctId":"NCT03289325","phase":"NA","title":"Dexmedetomidine and Long-term Outcomes in Elderly Patients After Cardiac Surgery","status":"COMPLETED","sponsor":"Peking University First Hospital","startDate":"2021-10-21","conditions":"Cardiac Surgery, Dexmedetomidine, Long-term Outcome","enrollment":285},{"nctId":"NCT04144153","phase":"PHASE4","title":"Opioid Free Anesthesia and Bariatric Surgery","status":"COMPLETED","sponsor":"Northwell Health","startDate":"2021-08-09","conditions":"Postoperative Quality of Recovery","enrollment":58},{"nctId":"NCT06229054","phase":"EARLY_PHASE1","title":"Dexmedetomidine in Obturator Nerve Block as an Analgesic in Transurethral Surgeries","status":"COMPLETED","sponsor":"Cairo University","startDate":"2024-02-01","conditions":"Dexmedetomidine","enrollment":56},{"nctId":"NCT05264077","phase":"EARLY_PHASE1","title":"Efficacy of Dexmedetomidine vs Midazolam for Early Extubation in Critically Ill Agitated Patients Undergoing Weaning","status":"NOT_YET_RECRUITING","sponsor":"Sheikh Zayed Medical College","startDate":"2024-11-01","conditions":"Agitation, Emergence","enrollment":66},{"nctId":"NCT03809442","phase":"PHASE4","title":"Analgesic Efficacy of Ropivacaine Alone or in Combination With Adjuvants on Post-operative Analgesia Following Video-Assisted Thoracoscopic Surgery.","status":"COMPLETED","sponsor":"Aga Khan University","startDate":"2019-06-25","conditions":"Postoperative Analgesia","enrollment":116},{"nctId":"NCT06493396","phase":"NA","title":"Effect of Opioid-free Anesthesia on Sleep Quality, Cognitive Function and Recovery Quality After General Anesthesia in Elderly Patients","status":"NOT_YET_RECRUITING","sponsor":"Beijing Friendship Hospital","startDate":"2024-08-01","conditions":"Opioid-Free Anesthesia, POCD, Recovery Quality","enrollment":88},{"nctId":"NCT04042727","phase":"PHASE2, PHASE3","title":"Controlling Rapid Atrial Fibrillation With Dexmedetomidine","status":"TERMINATED","sponsor":"Stony Brook University","startDate":"2019-08-21","conditions":"Rapid Atrial Fibrillation, Heart Rate Control","enrollment":13},{"nctId":"NCT06305221","phase":"NA","title":"Effect of Opioid-free Analgesia and Anesthesia on the Quality of Postoperative Recovery and Nausea Vomit in Patients Receiving Laparoscopic Sleeve Gastrectomy","status":"RECRUITING","sponsor":"Beijing Friendship Hospital","startDate":"2024-03-09","conditions":"Opioid-Free Anesthesia, Laparoscopic Sleeve Gastrectomy, Postoperative Vomiting","enrollment":76},{"nctId":"NCT05466708","phase":"PHASE4","title":"Safety and Efficacy of Esketamine Combined With Dexmedetomidine for Sedation of Mechanically Ventilated Patients","status":"RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2022-08-11","conditions":"Dexmedetomidine, Ketamine, Analgesia","enrollment":100},{"nctId":"NCT05552391","phase":"PHASE4","title":"Dexametomedine Versus Ketamine as an Adjuvant in Erector Spinae Block for Perioperative Thoracotomy Pain Control","status":"COMPLETED","sponsor":"Kasr El Aini Hospital","startDate":"2022-09-01","conditions":"Post Operative Pain","enrollment":90},{"nctId":"NCT06366412","phase":"PHASE4","title":"Dexmedetomidine on Postoperative Cognitive Dysfunction and Serum Tau-217 Protein.","status":"RECRUITING","sponsor":"Minia University Hospital","startDate":"2024-04","conditions":"Cognitive Impairment","enrollment":94},{"nctId":"NCT06354478","phase":"NA","title":"IV Dexmedetomidine vs Oral Gabapentin and Their Combination for Postoperative Analgesia in Cancer Patients Undergoing Modified Radical Mastectomy","status":"COMPLETED","sponsor":"National Cancer Institute, Egypt","startDate":"2021-01-01","conditions":"Breast Cancer, Pain, Postoperative, Pain, Acute","enrollment":90},{"nctId":"NCT06207344","phase":"NA","title":"The Anesthesia Effects of Dexmedetomidine Combined With Desflurane or Propofol in Lobectomy","status":"RECRUITING","sponsor":"The Second Affiliated Hospital of Chongqing Medical University","startDate":"2023-10-21","conditions":"Anesthesia Recovery Period, Postoperative Complications","enrollment":120},{"nctId":"NCT05775861","phase":"NA","title":"Dexmedetomidine Added to Ropivacaine Single Shot vs Continuous Interscalene Nerve Block","status":"UNKNOWN","sponsor":"Ciusss de L'Est de l'Île de Montréal","startDate":"2022-08-23","conditions":"Anesthesia, Shoulder Pain, Post Operative Pain","enrollment":96},{"nctId":"NCT04040439","phase":"","title":"Precedex Special Investigation (in Pediatric Patients)","status":"COMPLETED","sponsor":"Pfizer","startDate":"2019-07-30","conditions":"Sedation","enrollment":111},{"nctId":"NCT06199011","phase":"NA","title":"Effect of Esketamine on Depressive Symptoms of Obese Patients Undergoing Laparoscopic Sleeve Gastrectomy","status":"UNKNOWN","sponsor":"The Second Hospital of Anhui Medical University","startDate":"2024-01-01","conditions":"Depressive Symptoms","enrollment":400},{"nctId":"NCT06169475","phase":"NA","title":"Effect of Dexmedetomidine vs Esmolol or Placebo on Cerebral Hemodynamics in Septic Shock","status":"COMPLETED","sponsor":"Xinchen Wang","startDate":"2020-11-01","conditions":"Septic Shock, Stress Response, Cerebral Hemodynamics","enrollment":14},{"nctId":"NCT04082767","phase":"PHASE3","title":"Sedation Efficacy of Dexmedetomidine Versus Midazolam in Critically Ill Ventilated Children","status":"UNKNOWN","sponsor":"Douglas Fraser","startDate":"2021-06-08","conditions":"Mechanically Ventilated, Critically Ill Children","enrollment":120},{"nctId":"NCT05850455","phase":"NA","title":"Lumbar Epidural Analgesia Versus Local Anesthesia With Dexmedetomidine Infusion in Endoscopic Lumbar Discectomy","status":"COMPLETED","sponsor":"Ain Shams University","startDate":"2023-05-20","conditions":"Lumbar Disc Herniation","enrollment":78},{"nctId":"NCT05993975","phase":"PHASE4","title":"Effects of Intrathecal Dexmedetomidine as an Adjuvant to Low Dose Hyperbaric 0.5% Bupivacaine","status":"COMPLETED","sponsor":"Sindh Institute of Urology and Transplantation","startDate":"2021-07-20","conditions":"Post Operative Pain","enrollment":108},{"nctId":"NCT04827056","phase":"PHASE1","title":"Effect of Sublingual Formulation of Dexmedetomidine HCl (BXCL501) - Alcohol Interaction Study","status":"COMPLETED","sponsor":"Pharmacotherapies for Alcohol and Substance Use Disorders Alliance","startDate":"2021-11-09","conditions":"Alcohol Use Disorder (AUD), Post Traumatic Stress Disorder (PTSD)","enrollment":10},{"nctId":"NCT03892928","phase":"NA","title":"Safety and Efficacy of Dexmedetomidine in Painless Colonoscopy","status":"COMPLETED","sponsor":"West China Hospital","startDate":"2019-12-01","conditions":"Colonoscopy","enrollment":104},{"nctId":"NCT05692167","phase":"PHASE2","title":"Dexmedetomidine in Topical Versus Peribulbar Anesthesia for Cataract Surgery","status":"UNKNOWN","sponsor":"Kafrelsheikh University","startDate":"2023-07-15","conditions":"Dexmedetomidine, Cataract Surgery, Peribulbar","enrollment":94},{"nctId":"NCT05134363","phase":"NA","title":"Dexmedetomidine for Prophylaxis Against PONV in Highly Susceptible Patients.","status":"COMPLETED","sponsor":"Cairo University","startDate":"2021-08-11","conditions":"Postoperative Nausea and Vomiting, Head and Neck Surgeries","enrollment":180},{"nctId":"NCT05579964","phase":"PHASE2, PHASE3","title":"The Role of Dexmedetomidine as Myocardial Protector in Pediatric Cardiac Surgery Total Correction of Tetralogy of Fallot","status":"COMPLETED","sponsor":"National Cardiovascular Center Harapan Kita Hospital Indonesia","startDate":"2022-10-10","conditions":"Congenital Heart Disease in Children, Cardiopulmonary Bypass, Tetralogy of Fallot","enrollment":66},{"nctId":"NCT05998551","phase":"NA","title":"Single Shot Intrathecal Analgesia in Vaginal Delivery","status":"UNKNOWN","sponsor":"Ain Shams University","startDate":"2023-01-01","conditions":"Effectiveness of Single Shot Intra-thecal Analgesia in Multiparous Women Scheduled for Normal Vaginal Delivery","enrollment":75},{"nctId":"NCT05674877","phase":"PHASE3","title":"Opioid Sparing Anesthesia in Patients With Liver Cirrhosis Undergoing Liver Resection","status":"COMPLETED","sponsor":"Cairo University","startDate":"2022-12-01","conditions":"Liver Cirrhosis","enrollment":100},{"nctId":"NCT03078946","phase":"PHASE4","title":"Dexmedetomidine Versus Morphine and Midazolam in Prevention and Treatment of Delirium After Adult Cardiac Surgery","status":"COMPLETED","sponsor":"Ain Shams University","startDate":"2013-03","conditions":"Delirium","enrollment":60},{"nctId":"NCT02923128","phase":"PHASE4","title":"Whether Dexmedetomidine Can Improve the Prognosis of Elderly Patients With Postoperative Cognitive Dysfunction","status":"COMPLETED","sponsor":"Zhejiang Cancer Hospital","startDate":"2016-11","conditions":"Postoperative Cognitive Dysfunction, Postoperative Delirium","enrollment":240},{"nctId":"NCT05919173","phase":"PHASE4","title":"Comparison Between Bupivacaine and Bupivacaine With Dexmedetomidine in Caudal Block for Post Operative Pain Control","status":"COMPLETED","sponsor":"Sindh Institute of Urology and Transplantation","startDate":"2021-07-10","conditions":"Post Operative Pain","enrollment":60},{"nctId":"NCT05727098","phase":"PHASE2, PHASE3","title":"Dexmedetomedine and Ketamine in Erector Spinae Block for Postoperative Analgesia Following Mastectomy.","status":"COMPLETED","sponsor":"National Cancer Institute, Egypt","startDate":"2023-01-01","conditions":"Breast Cancer","enrollment":75},{"nctId":"NCT04942340","phase":"PHASE1","title":"Turning Dexmedetomidine Into a Powerful Anesthetic That Can be Rapidly and Completely Reversed","status":"WITHDRAWN","sponsor":"University of Chicago","startDate":"2023-05","conditions":"Emergence From Anesthesia","enrollment":0},{"nctId":"NCT05341154","phase":"NA","title":"Ketamine Versus Dexmedetomidine for Prevention of Postoperative Delirium","status":"COMPLETED","sponsor":"Huda Fahmy Mahmoud, PhD","startDate":"2021-12-01","conditions":"Emergence Delirium","enrollment":60},{"nctId":"NCT05828199","phase":"PHASE1","title":"The Effect of Intraoperative Infusion of Dexmedetomidine Versus Low Dose Ketamine","status":"UNKNOWN","sponsor":"Al-Azhar University","startDate":"2022-12-01","conditions":"Nasal Polyps, Nasal Septum, Irregular, Functional Endoscopic Sinus Surgery","enrollment":80},{"nctId":"NCT05813106","phase":"PHASE4","title":"Intravenous Dexmedetomidine for Emergence Delirium in Pediatric Patient","status":"UNKNOWN","sponsor":"Security Forces Hospital","startDate":"2022-12-01","conditions":"Emergence Delirium, Dexmeditomidine","enrollment":60},{"nctId":"NCT03530371","phase":"PHASE3","title":"Intranasal Dexmedetomidine for Sedated Hearing Testing","status":"COMPLETED","sponsor":"Fondation Lenval","startDate":"2019-05-02","conditions":"Auditory Brainstem Response","enrollment":60},{"nctId":"NCT05631028","phase":"NA","title":"95% Effective Dose(ED95) of Remimazolam During Dexmedetomidine Pretreatment","status":"COMPLETED","sponsor":"Shiyou Wei","startDate":"2022-12-01","conditions":"Lung Cancer, Anesthesia Induction","enrollment":115},{"nctId":"NCT04260659","phase":"PHASE4","title":"Opioid Free vs Opioid Based Anesthesia for Laparoscopic Sleeve Gastrectomy","status":"COMPLETED","sponsor":"Medical University of Warsaw","startDate":"2020-02-04","conditions":"Obesity, Postoperative Pain, Postoperative Nausea","enrollment":59},{"nctId":"NCT05216055","phase":"PHASE2","title":"Transverse Abdominus Plane Block Study","status":"WITHDRAWN","sponsor":"University of Colorado, Denver","startDate":"2022-04-19","conditions":"Colorectal Disorders, Surgery","enrollment":0},{"nctId":"NCT05615194","phase":"NA","title":"The Impact of a Single Dexmedetomidine Bolus on Intraoperative Sevoflurane Consumption (DEXHALE)","status":"UNKNOWN","sponsor":"Ciusss de L'Est de l'Île de Montréal","startDate":"2022-12-05","conditions":"Inhalation Anesthesia, Dexmedetomidine, Sevoflurane","enrollment":84},{"nctId":"NCT05698758","phase":"NA","title":"Intranasal Dexmedetomidine for Adult Patients Undergoing Phacoemulsification Cataract Surgery","status":"UNKNOWN","sponsor":"Guangzhou First People's Hospital","startDate":"2023-01-10","conditions":"Cataract, Preoperative Sedation","enrollment":64},{"nctId":"NCT04906889","phase":"NA","title":"the Effect of Dexmedetomidine and Licodaine on Acute Postoperative Pain in Gynecological Laparoscopy","status":"WITHDRAWN","sponsor":"The Catholic University of Korea","startDate":"2021-06-01","conditions":"Gynecologic Disease","enrollment":0},{"nctId":"NCT04391855","phase":"PHASE4","title":"Wound Infiltration With Tramadol, Dexmedetomidine, or Magnesium Plus Ropivacaine for Pain Relief After Spine Surgery","status":"COMPLETED","sponsor":"Aristotle University Of Thessaloniki","startDate":"2020-05-10","conditions":"Analgesia, Pain, Postoperative, Spinal Stenosis","enrollment":72},{"nctId":"NCT04608331","phase":"PHASE4","title":"Dexmedetomidine Supplemented Analgesia in Patients at High-risk of Obstructive Sleep Apnea","status":"COMPLETED","sponsor":"Peking University First Hospital","startDate":"2021-01-29","conditions":"Obstructive Sleep Apnea, Analgesia, Dexmedetomidine","enrollment":152},{"nctId":"NCT04206059","phase":"NA","title":"Closed Loop Acoustic Stimulation During Sedation With Dexmedetomidine","status":"ACTIVE_NOT_RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2021-01-20","conditions":"Sleep, Sedation Complication","enrollment":20},{"nctId":"NCT05622656","phase":"PHASE4","title":"Dexmedetomidine Reduce Postoperative Pain of C-section","status":"UNKNOWN","sponsor":"First People's Hospital of Chenzhou","startDate":"2022-12-01","conditions":"Pain, Postoperative","enrollment":80},{"nctId":"NCT05111431","phase":"PHASE3","title":"A Trial of Dexmedetomidine Hydrochloride Nasal Spray in Preoperative Sedation of Children","status":"COMPLETED","sponsor":"Shanghai Hengrui Pharmaceutical Co., Ltd.","startDate":"2021-11-24","conditions":"Preoperative Sedation of Children","enrollment":159},{"nctId":"NCT05300802","phase":"PHASE2, PHASE3","title":"The Role of Dexmedetomidine As Myocardial Protection In Pediatric Cyanotic Congenital Heart Disease Undergoing Open Cardiac Surgery Using Cardiopulmonary Bypass Machine: A Preliminary Study","status":"COMPLETED","sponsor":"National Cardiovascular Center Harapan Kita Hospital Indonesia","startDate":"2021-12-16","conditions":"Congenital Heart Disease in Children, Cardiopulmonary Bypass","enrollment":15},{"nctId":"NCT05361642","phase":"NA","title":"Regional Nasal Block and Dexmedetomidine in Endoscopic Sinus Surgery","status":"UNKNOWN","sponsor":"Ain Shams University","startDate":"2022-02-03","conditions":"Drug Use","enrollment":70}],"_emaApprovals":[{"date":"","name":"Dexmedetomidine Hydrochloride","status":"Authorised","regulator":"EMA"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[{"role":"Manufacturer","site":"Fresenius Kabi USA, LLC","location":"","operator":"Fresenius Kabi USA, LLC"}],"molecularData":{"oral":false,"chemblId":"CHEMBL2106195","moleculeType":"Small molecule","molecularWeight":"236.75"},"administration":{"route":"Intravenous","formulations":[{"form":"FILM","route":"SUBLINGUAL","tradeName":"IGALMI"},{"form":"INJECTION","route":"INTRAVENOUS","tradeName":"DEXMEDETOMIDINE HYDROCHLORIDE"},{"form":"INJECTION","route":"INTRAVENOUS","tradeName":"DEXMEDETOMIDINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE"},{"form":"INJECTION","route":"INTRAVENOUS","tradeName":"Dexmedetomidine HCl"},{"form":"INJECTION","route":"INTRAVENOUS","tradeName":"Dexmedetomidine Hydrochloride"},{"form":"INJECTION","route":"INTRAVENOUS","tradeName":"Dexmedetomidine Hydrochloride"},{"form":"INJECTION, SOLUTION","route":"INTRAVENOUS","tradeName":"DEXMEDETOMIDINE"},{"form":"INJECTION, SOLUTION","route":"INTRAVENOUS","tradeName":"DEXMEDETOMIDINE HYDROCHLORIDE"},{"form":"INJECTION, SOLUTION","route":"INTRAVENOUS","tradeName":"Dexmedetomidine"},{"form":"INJECTION, SOLUTION","route":"INTRAVENOUS","tradeName":"Dexmedetomidine Hydrochloride"}]},"_patentsChecked":true,"_warningLetters":[{"date":"03/28/2023","subject":"11/07/2022\tTodos Medical Ltd aka Todos Medical USA Inc\tCenter for Food Safety and Applied Nutrition"},{"date":"03/27/2026","subject":"Feedback form"}],"crossReferences":{"NUI":"N0000148660","MMSL":"227894","NDDF":"008084","UNII":"67VB76HONO","VUID":"4021214","CHEBI":"CHEBI:4466","VANDF":"4021214","INN_ID":"6277","RXNORM":"228054","UMLSCUI":"C0113293","chemblId":"CHEMBL2106195","ChEMBL_ID":"CHEMBL778","KEGG_DRUG":"D00514","DRUGBANK_ID":"DB00633","PDB_CHEM_ID":"CZX","PUBCHEM_CID":"5311068","SNOMEDCT_US":"116348007","IUPHAR_LIGAND_ID":"521","SECONDARY_CAS_RN":"145108-58-3","MESH_DESCRIPTOR_UI":"D020927"},"formularyStatus":[],"_offLabelChecked":true,"developmentCodes":[],"ownershipHistory":[{"period":"1999-present","_source":"FDA label","companyName":"Pfizer","relationship":"Originator"}],"pharmacokinetics":{"source":"DrugCentral","halfLife":"2.2 hours","clearance":"11.0 mL/min/kg","fractionUnbound":"0.06%","volumeOfDistribution":"1.6 L/kg"},"publicationCount":103,"therapeuticAreas":["Cardiovascular"],"atcClassification":{"source":"DrugCentral","atcCode":"N05CM18","allCodes":["N05CM18"]},"biosimilarFilings":[],"recentPublications":[],"_drugWebsiteChecked":true,"_healthCanadaChecked":true,"companionDiagnostics":[],"_genericFilersChecked":true,"genericManufacturerList":[],"phase":"marketed","status":"approved","companyName":"Pfizer","companyId":"pfizer","modality":"small molecule","firstApprovalDate":"1999","enrichmentLevel":4,"visitCount":6,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2013-09-28T00:00:00.000Z","mah":"HOSPIRA","brand_name_local":null,"application_number":"NDA021038"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2018-11-29T00:00:00.000Z","mah":"FRESENIUS KABI USA","brand_name_local":null,"application_number":"ANDA208129"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2020-08-27T00:00:00.000Z","mah":"MYLAN LABS LTD","brand_name_local":null,"application_number":"ANDA212571"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2023-11-28T00:00:00.000Z","mah":"FRESENIUS KABI USA","brand_name_local":null,"application_number":"ANDA201072"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2024-09-24T00:00:00.000Z","mah":"SOMERSET","brand_name_local":null,"application_number":"ANDA218112"},{"country_code":"AR","regulator":"ANMAT","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TR","regulator":"TITCK","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IN","regulator":"CDSCO","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TH","regulator":"FDA-TH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"MY","regulator":"NPRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"PH","regulator":"FDA-PH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"CO","regulator":"INVIMA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"ZA","regulator":"SAHPRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TW","regulator":"TFDA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"HK","regulator":"DH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"EU","regulator":"EMA","status":"pending","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"BR","regulator":"ANVISA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"MX","regulator":"COFEPRIS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"patentsNormalised":[{"patent_number":"8242158","territory":"US","patent_type":null,"expiry_date":"2032-01-04T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"9616049","territory":"US","patent_type":null,"expiry_date":"2032-01-04T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"8648106","territory":"US","patent_type":null,"expiry_date":"2032-01-04T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"9320712","territory":"US","patent_type":null,"expiry_date":"2032-01-04T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"8455527","territory":"US","patent_type":null,"expiry_date":"2032-01-04T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"10016396","territory":"US","patent_type":null,"expiry_date":"2032-01-04T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"8338470","territory":"US","patent_type":null,"expiry_date":"2032-01-04T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"8242158*PED","territory":"US","patent_type":null,"expiry_date":"2032-07-04T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"8648106*PED","territory":"US","patent_type":null,"expiry_date":"2032-07-04T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"8455527*PED","territory":"US","patent_type":null,"expiry_date":"2032-07-04T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"8338470*PED","territory":"US","patent_type":null,"expiry_date":"2032-07-04T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"9320712*PED","territory":"US","patent_type":null,"expiry_date":"2032-07-04T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"9616049*PED","territory":"US","patent_type":null,"expiry_date":"2032-07-04T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"9717796","territory":"US","patent_type":null,"expiry_date":"2036-04-20T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"9649296","territory":"US","patent_type":null,"expiry_date":"2036-04-20T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"11517524","territory":"US","patent_type":null,"expiry_date":"2039-06-26T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"11497711","territory":"US","patent_type":null,"expiry_date":"2039-06-26T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"10792246","territory":"US","patent_type":null,"expiry_date":"2039-06-26T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"11478422","territory":"US","patent_type":null,"expiry_date":"2039-06-26T00:00:00.000Z","status":"active","paragraph_iv_filed":false}],"pricingByCountry":[{"country_code":"US","currency":"USD","price_amount":"1.68","price_per":"year","price_type":"annual_list","annual_cost_usd":null,"reimbursement_status":null}],"trialStats":{"total":32,"withResults":3},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-19T23:53:50.295370+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}